<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03572062</url>
  </required_header>
  <id_info>
    <org_study_id>C3671002</org_study_id>
    <secondary_id>RSV ADJUVANT</secondary_id>
    <nct_id>NCT03572062</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Safety and Immunogenicity of an Adjuvanted RSV Vaccine in Healthy Older Adults</brief_title>
  <official_title>A PHASE 1/2, PLACEBO-CONTROLLED, RANDOMIZED, OBSERVER-BLIND,DOSE-FINDING, FIRST-IN-HUMAN STUDY TO DESCRIBE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF AN ADJUVANTED RESPIRATORY SYNCYTIAL VIRUS (RSV) VACCINE IN HEALTHY OLDER ADULTS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will evaluate the safety, tolerability, and immunogenicity of up to 7 different RSV&#xD;
      vaccine candidates, some with adjuvant, when administered concomitantly with seasonal&#xD;
      inactivated influenza vaccine (SIIV) and may evaluate a second dose of RSV vaccine&#xD;
      administered12 months after the initial dose.&#xD;
&#xD;
      In addition the study will evaluate a 2-dose regimen administered 2 months apart to 62&#xD;
      subjects.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will evaluate the safety, tolerability, and immunogenicity of up to 7 different RSV&#xD;
      vaccine candidates, some with adjuvant, when administered concomitantly with SIIV. Healthy&#xD;
      male and female subjects between 65 to 85 years of age will be enrolled. Subjects will&#xD;
      receive 2 intramuscular injections to assess the concomitant administration of SIIV when&#xD;
      given to subjects receiving one of the 3 RSV vaccine dose-level candidates formulated with or&#xD;
      without an adjuvant.&#xD;
&#xD;
      If interim support implementation of revaccination, invited, consenting subjects will be&#xD;
      revaccinated with the same dose and formulation of the RSV vaccine or placebo received at&#xD;
      Visit 1, concomitantly with SIIV. The safety, tolerability, and immunogenicity of the second&#xD;
      dose will be evaluated through 12 months after revaccination.&#xD;
&#xD;
      62 subjects will be randomized 1:1 to receive a dose of high dose adjuvanted RSV vaccine or&#xD;
      placebo followed by a second dose 2 months later. Safety, tolerability, and immunogenicity&#xD;
      will be evaluated. The subjects will be enrolled before the influenza season. There will be&#xD;
      no concomitant SIIV administration.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Study halted prematurely by sponsor and will not resume, participants are no longer being&#xD;
    examined or receiving intervention.&#xD;
  </why_stopped>
  <start_date type="Actual">June 5, 2018</start_date>
  <completion_date type="Actual">August 19, 2020</completion_date>
  <primary_completion_date type="Actual">June 23, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Parallel</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Observer blind</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Primary Cohort: Percentage of Participants With Local Reactions Within 14 Days After Vaccination 1</measure>
    <time_frame>Within 14 days after Vaccination 1</time_frame>
    <description>Local reactions included redness, swelling, and pain at the injection site (left arm) recorded by participants in an electronic diary (e-diary). Redness and swelling were measured and recorded in measuring device units (range: 1 to 20, and greater than [&gt;] 21). 1 measuring device unit = 0.5 centimeter (cm) and graded as: mild (2.5 to 5.0 cm), moderate (greater than [&gt;] 5.0 to 10.0 cm), and severe (&gt;10 cm). Pain at injection site was graded as: mild (did not interfere with activity), moderate (interferes with activity) and severe (prevented daily activity).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Primary Cohort: Percentage of Participants With Systemic Events Within 14 Days After Vaccination 1</measure>
    <time_frame>Within 14 days after Vaccination 1</time_frame>
    <description>Systemic events included fever, fatigue/tiredness, headache, vomiting, nausea, diarrhea, muscle pain and joint pain recorded by participants in an e-diary. Fever was graded as: mild (38.0 to 38.4 degrees [deg] Celsius [C]), moderate (38.5 to 38.9 deg C), severe (39 deg C to 40.0 deg C) and grade 4 (&gt;40.0 deg C). Fatigue, headache, nausea, muscle and joint pain were graded as: mild (did not interfere with activity), moderate (some interference with activity) and severe (prevented daily routine activity). Vomiting was graded as: mild (1-2 times in 24 hours [h]), moderate (&gt;2 times in 24h) and severe (required intravenous hydration). Diarrhea was graded as: mild (2-3 loose stools in 24h), moderate (4-5 loose stools in 24h) and severe (6 or more loose stools in 24h).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Primary Cohort: Percentage of Participants With Adverse Events (AEs) Within 1 Month After Vaccination 1</measure>
    <time_frame>Within 1 month after Vaccination 1</time_frame>
    <description>An AE is any untoward medical occurrence in a study participant administered a product or medical device; the event need not necessarily have a causal relationship with the treatment or usage. AEs included both serious and non-serious adverse events.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Primary Cohort: Percentage of Participants With Medically Attended Adverse Events (MAEs) and Serious Adverse Events (SAEs) Through 12 Months After Vaccination 1</measure>
    <time_frame>Up to 12 months after Vaccination 1</time_frame>
    <description>An MAE was defined as a non-serious AE that resulted in an evaluation at a medical facility. A SAE is any untoward medical occurrence at any dose: results in death; is life-threatening (immediate risk of death); requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity (substantial disruption of the ability to conduct normal life functions); results in congenital anomaly/birth defect.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Primary Cohort: Geometric Mean Titers (GMT) of Respiratory Syncytial Virus Subgroup A (RSV A) and Respiratory Syncytial Virus Subgroup B (RSV B) Neutralizing Antibodies Before and 1 Month After Vaccination 1</measure>
    <time_frame>Before vaccination and 1 Month after Vaccination 1</time_frame>
    <description>GMTs of RSV A and RSV B antigens were measured using neutralizing assay. Titers above the lower limit of quantitation (LLOQ) were considered accurate and their quantitated values were reported. The neutralizing titer LLOQ values were: A = 50 and B = 70. Assay results below the LLOQ were set to 0.5 × LLOQ.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Primary Cohort: Hemagglutination Inhibition Assay (HAI) and Neutralizing Antibody Geometric Mean Titers for All Strains Following the Seasonal Inactivated Influenza Vaccine (SIIV) Before and 1 Month After Vaccination 1</measure>
    <time_frame>Before vaccination and 1 Month after Vaccination 1</time_frame>
    <description>The HAI and neutralizing titer LLOQ value for each strain was 1:10. Assay results below the LLOQ were set to 0.5 × LLOQ. The analysis was performed on following strains: H1N1 A/Michigan, H3N2 A/Brisbane, B/Phuket for HAI and H3N2/Brisbane for neutralizing assay.</description>
  </secondary_outcome>
  <number_of_arms>10</number_of_arms>
  <enrollment type="Actual">317</enrollment>
  <condition>Respiratory Tract Infection</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Low dose formulation A and SIIV</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Low dose formulation B and SIIV</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Mid dose formulation A and SIIV</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Mid dose formulation B and SIIV</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>High dose formulation A and SIIV</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>High dose formulation B and SIIV</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 7</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>High dose formulation C and SIIV</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 8</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo and SIIV</description>
  </arm_group>
  <arm_group>
    <arm_group_label>M0M2 Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>High dose formulation B</description>
  </arm_group>
  <arm_group>
    <arm_group_label>M0M2 Arm 2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Formulation A</intervention_name>
    <description>RSV vaccine</description>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_label>Arm 3</arm_group_label>
    <arm_group_label>Arm 5</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Formulation B</intervention_name>
    <description>Adjuvanted RSV vaccine</description>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_label>Arm 4</arm_group_label>
    <arm_group_label>Arm 6</arm_group_label>
    <arm_group_label>M0M2 Arm 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Formulation C</intervention_name>
    <description>RSV vaccine</description>
    <arm_group_label>Arm 7</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Arm 8</arm_group_label>
    <arm_group_label>M0M2 Arm 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Evidence of a personally signed and dated informed consent document (ICD) indicating&#xD;
             that the subject has been informed of all pertinent aspects of the study.&#xD;
&#xD;
          2. Healthy adults who are determined by medical history, physical examination, and&#xD;
             clinical judgment of the investigator to be eligible for inclusion in the study.&#xD;
&#xD;
          3. Willing and able to comply with scheduled visits, vaccination plan, laboratory tests,&#xD;
             and other study procedures.&#xD;
&#xD;
          4. Male and nonchildbearing-potential female adults aged 65 to 85 years at the time of&#xD;
             enrollment (signing of the ICD).&#xD;
&#xD;
          5. Subjects must have received the primary vaccination (RSV vaccine or placebo) at Visit&#xD;
             1 and have signed and dated the ICD for participating in the revaccination stage&#xD;
             (applies to Primary Study Cohort - Stage 2 subjects).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Investigator site staff members directly involved in the conduct of the study and&#xD;
             their family members, site staff members otherwise supervised by the investigator, or&#xD;
             subjects who are Pfizer employees, including their family members, directly involved&#xD;
             in the conduct of the study.&#xD;
&#xD;
          2. Participation in other studies involving investigational product within 28 days prior&#xD;
             to study entry and/or during study participation.&#xD;
&#xD;
          3. Known infection with HIV, hepatitis C virus (HCV), or hepatitis B virus (HBV).&#xD;
&#xD;
          4. Previous vaccination with any licensed or investigational RSV vaccine before&#xD;
             enrollment into the study, or planned receipt throughout the study of nonstudy RSV&#xD;
             vaccine.&#xD;
&#xD;
          5. Vaccination with any influenza vaccine within 6 months (182 days) before&#xD;
             investigational product administration (applies to Primary Study Cohort - Stages 1 and&#xD;
             2).&#xD;
&#xD;
          6. History of severe adverse reaction associated with a vaccine and/or severe allergic&#xD;
             reaction (eg, anaphylaxis) to any component of the investigational product(s),&#xD;
             including natural rubber latex. In addition, a history of severe allergic reaction&#xD;
             (eg, anaphylaxis) to any substance, including documented allergy to egg proteins (egg&#xD;
             or egg products) or chicken proteins.&#xD;
&#xD;
          7. Subjects with known or suspected immunodeficiency, as determined by history and/or&#xD;
             laboratory/physical examination.&#xD;
&#xD;
          8. Subjects who receive treatment with immunosuppressive therapy, including cytotoxic&#xD;
             agents or systemic corticosteroids, eg, for cancer or an autoimmune disease, or&#xD;
             planned receipt throughout the study. If systemic corticosteroids have been&#xD;
             administered short term (&lt;14 days) for treatment of an acute illness, subjects should&#xD;
             not be enrolled into the study until corticosteroid therapy has been discontinued for&#xD;
             at least 28 days before investigational product administration.Inhaled/nebulized,&#xD;
             intra-articular, intrabursal, or topical (epidural, skin or eyes) corticosteroids are&#xD;
             permitted.&#xD;
&#xD;
          9. Subject with a history of autoimmune disease or an active autoimmune disease requiring&#xD;
             therapeutic intervention including but not limited to: systemic or cutaneous lupus&#xD;
             erythematosus, autoimmune arthritis/rheumatoid arthritis, Guillain-Barré&#xD;
             syndrome,multiple sclerosis, Sjögren syndrome, idiopathic thrombocytopenic purpura,&#xD;
             autoimmune glomerulonephritis, autoimmune thyroiditis, giant cell arteritis (temporal&#xD;
             arteritis), psoriasis, and insulin-dependent diabetes mellitus (type 1).&#xD;
&#xD;
         10. Receipt of blood/plasma products or immunoglobulin, from 60 days before&#xD;
             investigational product administration or planned receipt throughout the study.&#xD;
&#xD;
         11. Bleeding diathesis or condition associated with prolonged bleeding that would, in the&#xD;
             opinion of the investigator, contraindicate intramuscular injection.&#xD;
&#xD;
         12. Female subjects of childbearing potential or who are pregnant or breastfeeding;&#xD;
             fertile male subjects who are unwilling to use a highly effective method of&#xD;
             contraception for at least 28 days after the last dose of investigational product.&#xD;
&#xD;
         13. Other acute or chronic medical or psychiatric condition including recent (within the&#xD;
             past year) or active suicidal ideation or behavior or laboratory abnormality that may&#xD;
             increase the risk associated with study participation or investigational product&#xD;
             administration or may interfere with the interpretation of study results and, in the&#xD;
             judgment of the investigator, would make the subject inappropriate for entry into this&#xD;
             study.&#xD;
&#xD;
         14. Planned donation of blood volumes of approximately 470 mL within 12 weeks after&#xD;
             Vaccination 1 (applies to subjects having additional blood drawn for cellular assays).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Qps Mra, Llc</name>
      <address>
        <city>South Miami</city>
        <state>Florida</state>
        <zip>33143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Optimal Research, LLC</name>
      <address>
        <city>Peoria</city>
        <state>Illinois</state>
        <zip>61614</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synexus Clinical Research US</name>
      <address>
        <city>Fremont</city>
        <state>Nebraska</state>
        <zip>68025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Quality Clinical Research, Inc.</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Australian Clinical Research Network</name>
      <address>
        <city>Maroubra</city>
        <state>New South Wales</state>
        <zip>2035</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AIM Centre (Hunter Diabetes Centre)</name>
      <address>
        <city>Merewether</city>
        <state>New South Wales</state>
        <zip>2291</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Holdsworth House Medical Practice</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2010</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Westmead Hospital (Infectious Diseases and Microbiology)</name>
      <address>
        <city>Westmead</city>
        <state>New South Wales</state>
        <zip>2145</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Data Health Australia Pty Limited (Trading as AusTrials)</name>
      <address>
        <city>Taringa</city>
        <state>Queensland</state>
        <zip>4068</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eastern Health</name>
      <address>
        <city>Box Hill</city>
        <state>Victoria</state>
        <zip>3128</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emeritus Research Pty. Ltd.</name>
      <address>
        <city>Camberwell</city>
        <state>Victoria</state>
        <zip>3124</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Monash Medical Centre</name>
      <address>
        <city>Clayton</city>
        <state>Victoria</state>
        <zip>3168</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Barwon Health</name>
      <address>
        <city>Geelong</city>
        <state>Victoria</state>
        <zip>3220</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Doctors of Ivanhoe</name>
      <address>
        <city>Ivanhoe</city>
        <state>Victoria</state>
        <zip>3079</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute for Respiratory Health</name>
      <address>
        <city>Nedlands</city>
        <state>Western Australia</state>
        <zip>6009</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>TrialsWest</name>
      <address>
        <city>Spearwood</city>
        <state>Western Australia</state>
        <zip>6163</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://pmiform.com/clinical-trial-info-request?StudyID=C3671002</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>June 1, 2018</study_first_submitted>
  <study_first_submitted_qc>June 18, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 28, 2018</study_first_posted>
  <results_first_submitted>June 21, 2021</results_first_submitted>
  <results_first_submitted_qc>August 25, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">August 26, 2021</results_first_posted>
  <last_update_submitted>August 25, 2021</last_update_submitted>
  <last_update_submitted_qc>August 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Respiratory tract infection, RSV, Adjuvant, vaccine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Tract Infections</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.</ipd_description>
    <ipd_url>https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests</ipd_url>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>August 22, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/62/NCT03572062/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 9, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/62/NCT03572062/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>This study was conducted in 2 Cohorts: Primary Cohort (Single administration of RSVpreF formulations or placebo, co-administered with seasonal inactivated influenza vaccine [SIIV]), and Month-0, Month-2 Cohort (two doses of an RSVpreF formulation or placebo administered two months apart).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Primary Cohort: RSVpreF 60 mcg + Al(OH)3 + SIIV</title>
          <description>Participants were administered an intramuscular dose of respiratory syncytial virus stabilized prefusion F subunit (RSVpreF) 60 microgram (mcg) with aluminum hydroxide (Al[OH]3) by injecting 0.5 milliliter (mL) dose along with single 0.5mL intramuscular dose of SIIV on Day 1. Participants were followed-up through Month 12.</description>
        </group>
        <group group_id="P2">
          <title>Primary Cohort: RSVpreF 60 mcg + CpG/Al(OH)3 + SIIV</title>
          <description>Participants were administered an intramuscular dose of RSVpreF 60 mcg with CpG/Al(OH)3 as 0.5-mL injection along with single 0.5 mL intramuscular dose of SIIV on Day 1. Participants were followed-up through Month 12.</description>
        </group>
        <group group_id="P3">
          <title>Primary Cohort: RSVpreF 120 mcg + Al(OH)3 + SIIV</title>
          <description>Participants were administered an intramuscular dose of RSVpreF 120 mcg with Al(OH)3 as 0.5-mL injection along with single 0.5 mL intramuscular dose of SIIV on Day 1. Participants were followed-up through Month 12.</description>
        </group>
        <group group_id="P4">
          <title>Primary Cohort: RSVpreF 120 mcg + CpG/Al(OH)3 + SIIV</title>
          <description>Participants were administered an intramuscular dose of RSVpreF 120 mcg with CpG/Al(OH)3 as 0.5-mL injection along with single 0.5 mL intramuscular dose of SIIV on Day 1. Participants were followed-up through Month 12.</description>
        </group>
        <group group_id="P5">
          <title>Primary Cohort: RSVpreF 240 mcg + Al(OH)3 + SIIV</title>
          <description>Participants were administered an intramuscular dose of RSVpreF 240 mcg with Al(OH)3 as 0.5-mL injection along with single 0.5 mL intramuscular dose of SIIV on Day 1. Participants were followed-up through Month 12.</description>
        </group>
        <group group_id="P6">
          <title>Primary Cohort: RSVpreF 240 mcg + CpG/Al(OH)3 + SIIV</title>
          <description>Participants were administered an intramuscular dose of RSVpreF 240 mcg with CpG/Al(OH)3 as 0.5-mL injection along with single 0.5 mL intramuscular dose of SIIV on Day 1. Participants were followed-up through Month 12.</description>
        </group>
        <group group_id="P7">
          <title>Primary Cohort: RSVpreF 240 mcg + SIIV</title>
          <description>Participants were administered an intramuscular dose of RSVpreF 240 mcg as 0.5-mL injection along with single 0.5 mL intramuscular dose of SIIV on Day 1. Participants were followed-up through Month 12.</description>
        </group>
        <group group_id="P8">
          <title>Primary Cohort: Placebo + SIIV</title>
          <description>Participants were administered an intramuscular dose of placebo intramuscularly as 0.5-mL injection along with single 0.5 mL intramuscular dose of SIIV on Day 1. Participants were followed-up through Month 12.</description>
        </group>
        <group group_id="P9">
          <title>Month-0, Month-2 Cohort: RSVpreF 240 mcg + CpG/Al(OH)3</title>
          <description>Participants were administered an intramuscular dose of RSVpreF 240 mcg with CpG/Al(OH)3 as 0.5-mL injection on Day 1 Month 0 (Vaccination 1) and Month 2 (Vaccination 2: 54 to 66 Days after Vaccination 1). Participants were followed up through 6 months after Vaccination 2.</description>
        </group>
        <group group_id="P10">
          <title>Month-0, Month-2 Cohort: Placebo</title>
          <description>Participants were administered an intramuscular dose of placebo as 0.5-mL injection on Day 1 Month 0 (Vaccination 1) and Month 2 (Vaccination 2: 54 to 66 Days after Vaccination 1). Participants were followed up through 6 months after Vaccination 2.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
                <participants group_id="P2" count="32"/>
                <participants group_id="P3" count="32"/>
                <participants group_id="P4" count="31"/>
                <participants group_id="P5" count="32"/>
                <participants group_id="P6" count="32"/>
                <participants group_id="P7" count="32"/>
                <participants group_id="P8" count="31"/>
                <participants group_id="P9" count="32"/>
                <participants group_id="P10" count="31"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treated</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
                <participants group_id="P2" count="32"/>
                <participants group_id="P3" count="32"/>
                <participants group_id="P4" count="31"/>
                <participants group_id="P5" count="31"/>
                <participants group_id="P6" count="30"/>
                <participants group_id="P7" count="32"/>
                <participants group_id="P8" count="30"/>
                <participants group_id="P9" count="32"/>
                <participants group_id="P10" count="31"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
                <participants group_id="P2" count="32"/>
                <participants group_id="P3" count="32"/>
                <participants group_id="P4" count="31"/>
                <participants group_id="P5" count="31"/>
                <participants group_id="P6" count="28"/>
                <participants group_id="P7" count="31"/>
                <participants group_id="P8" count="30"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="4"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="32"/>
                <participants group_id="P10" count="31"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="1"/>
                <participants group_id="P10" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>No Longer Meets Eligibility Criteria</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="1"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Study Terminated By Sponsor</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="29"/>
                <participants group_id="P10" count="27"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="1"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Randomized But Not Treated</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Safety population included all participants who received at least 1 dose of the investigational products (RSVpreF or placebo) at Visit 1.</population>
      <group_list>
        <group group_id="B1">
          <title>Primary Cohort: RSVpreF 60 mcg + Al(OH)3 + SIIV</title>
          <description>Participants were administered an intramuscular dose of respiratory syncytial virus stabilized prefusion F subunit (RSVpreF) 60 microgram (mcg) with aluminum hydroxide (Al[OH]3) by injecting 0.5 milliliter (mL) dose along with single 0.5mL intramuscular dose of SIIV on Day 1. Participants were followed-up through Month 12.</description>
        </group>
        <group group_id="B2">
          <title>Primary Cohort: RSVpreF 60 mcg + CpG/Al(OH)3 + SIIV</title>
          <description>Participants were administered an intramuscular dose of RSVpreF 60 mcg with CpG/Al(OH)3 as 0.5-mL injection along with single 0.5 mL intramuscular dose of SIIV on Day 1. Participants were followed-up through Month 12.</description>
        </group>
        <group group_id="B3">
          <title>Primary Cohort: RSVpreF 120 mcg + Al(OH)3 + SIIV</title>
          <description>Participants were administered an intramuscular dose of RSVpreF 120 mcg with Al(OH)3 as 0.5-mL injection along with single 0.5 mL intramuscular dose of SIIV on Day 1. Participants were followed-up through Month 12.</description>
        </group>
        <group group_id="B4">
          <title>Primary Cohort: RSVpreF 120 mcg + CpG/Al(OH)3 + SIIV</title>
          <description>Participants were administered an intramuscular dose of RSVpreF 120 mcg with CpG/Al(OH)3 as 0.5-mL injection along with single 0.5 mL intramuscular dose of SIIV on Day 1. Participants were followed-up through Month 12.</description>
        </group>
        <group group_id="B5">
          <title>Primary Cohort: RSVpreF 240 mcg + Al(OH)3 + SIIV</title>
          <description>Participants were administered an intramuscular dose of RSVpreF 240 mcg with Al(OH)3 as 0.5-mL injection along with single 0.5 mL intramuscular dose of SIIV on Day 1. Participants were followed-up through Month 12.</description>
        </group>
        <group group_id="B6">
          <title>Primary Cohort: RSVpreF 240 mcg + CpG/Al(OH)3 + SIIV</title>
          <description>Participants were administered an intramuscular dose of RSVpreF 240 mcg with CpG/Al(OH)3 as 0.5-mL injection along with single 0.5 mL intramuscular dose of SIIV on Day 1. Participants were followed-up through Month 12.</description>
        </group>
        <group group_id="B7">
          <title>Primary Cohort: RSVpreF 240 mcg + SIIV</title>
          <description>Participants were administered an intramuscular dose of RSVpreF 240 mcg as 0.5-mL injection along with single 0.5 mL intramuscular dose of SIIV on Day 1. Participants were followed-up through Month 12.</description>
        </group>
        <group group_id="B8">
          <title>Primary Cohort: Placebo + SIIV</title>
          <description>Participants were administered an intramuscular dose of placebo intramuscularly as 0.5-mL injection along with single 0.5 mL intramuscular dose of SIIV on Day 1. Participants were followed-up through Month 12.</description>
        </group>
        <group group_id="B9">
          <title>Month-0, Month-2 Cohort: RSVpreF 240 mcg + CpG/Al(OH)3</title>
          <description>Participants were administered an intramuscular dose of RSVpreF 240 mcg with CpG/Al(OH)3 as 0.5-mL injection on Day 1 Month 0 (Vaccination 1) and Month 2 (Vaccination 2: 54 to 66 Days after Vaccination 1). Participants were followed up through 6 months after Vaccination 2.</description>
        </group>
        <group group_id="B10">
          <title>Month-0, Month-2 Cohort: Placebo</title>
          <description>Participants were administered an intramuscular dose of placebo as 0.5-mL injection on Day 1 Month 0 (Vaccination 1) and Month 2 (Vaccination 2: 54 to 66 Days after Vaccination 1). Participants were followed up through 6 months after Vaccination 2.</description>
        </group>
        <group group_id="B11">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="32"/>
            <count group_id="B2" value="32"/>
            <count group_id="B3" value="32"/>
            <count group_id="B4" value="31"/>
            <count group_id="B5" value="31"/>
            <count group_id="B6" value="30"/>
            <count group_id="B7" value="32"/>
            <count group_id="B8" value="30"/>
            <count group_id="B9" value="32"/>
            <count group_id="B10" value="31"/>
            <count group_id="B11" value="313"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Mean</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="71.2" spread="5.4"/>
                    <measurement group_id="B2" value="71.0" spread="4.8"/>
                    <measurement group_id="B3" value="72.3" spread="4.5"/>
                    <measurement group_id="B4" value="70.2" spread="4.3"/>
                    <measurement group_id="B5" value="71.4" spread="5.3"/>
                    <measurement group_id="B6" value="70.2" spread="3.5"/>
                    <measurement group_id="B7" value="70.4" spread="5.4"/>
                    <measurement group_id="B8" value="70.8" spread="4.5"/>
                    <measurement group_id="B9" value="72.2" spread="4.4"/>
                    <measurement group_id="B10" value="72.6" spread="5.4"/>
                    <measurement group_id="B11" value="71.2" spread="4.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="17"/>
                    <measurement group_id="B4" value="16"/>
                    <measurement group_id="B5" value="13"/>
                    <measurement group_id="B6" value="11"/>
                    <measurement group_id="B7" value="12"/>
                    <measurement group_id="B8" value="14"/>
                    <measurement group_id="B9" value="16"/>
                    <measurement group_id="B10" value="17"/>
                    <measurement group_id="B11" value="145"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="15"/>
                    <measurement group_id="B4" value="15"/>
                    <measurement group_id="B5" value="18"/>
                    <measurement group_id="B6" value="19"/>
                    <measurement group_id="B7" value="20"/>
                    <measurement group_id="B8" value="16"/>
                    <measurement group_id="B9" value="16"/>
                    <measurement group_id="B10" value="14"/>
                    <measurement group_id="B11" value="168"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="32"/>
                    <measurement group_id="B3" value="32"/>
                    <measurement group_id="B4" value="31"/>
                    <measurement group_id="B5" value="30"/>
                    <measurement group_id="B6" value="30"/>
                    <measurement group_id="B7" value="32"/>
                    <measurement group_id="B8" value="30"/>
                    <measurement group_id="B9" value="32"/>
                    <measurement group_id="B10" value="31"/>
                    <measurement group_id="B11" value="312"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Race</title>
              <category_list>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="3"/>
                    <measurement group_id="B7" value="4"/>
                    <measurement group_id="B8" value="4"/>
                    <measurement group_id="B9" value="1"/>
                    <measurement group_id="B10" value="2"/>
                    <measurement group_id="B11" value="23"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="29"/>
                    <measurement group_id="B4" value="29"/>
                    <measurement group_id="B5" value="29"/>
                    <measurement group_id="B6" value="27"/>
                    <measurement group_id="B7" value="26"/>
                    <measurement group_id="B8" value="25"/>
                    <measurement group_id="B9" value="31"/>
                    <measurement group_id="B10" value="29"/>
                    <measurement group_id="B11" value="285"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="2"/>
                    <measurement group_id="B8" value="1"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Primary Cohort: Percentage of Participants With Local Reactions Within 14 Days After Vaccination 1</title>
        <description>Local reactions included redness, swelling, and pain at the injection site (left arm) recorded by participants in an electronic diary (e-diary). Redness and swelling were measured and recorded in measuring device units (range: 1 to 20, and greater than [&gt;] 21). 1 measuring device unit = 0.5 centimeter (cm) and graded as: mild (2.5 to 5.0 cm), moderate (greater than [&gt;] 5.0 to 10.0 cm), and severe (&gt;10 cm). Pain at injection site was graded as: mild (did not interfere with activity), moderate (interferes with activity) and severe (prevented daily activity).</description>
        <time_frame>Within 14 days after Vaccination 1</time_frame>
        <population>Safety population included all participants who received at least 1 dose of the investigational products (RSVpreF or placebo) at Visit 1. Here, &quot;Overall Number of Participants Analyzed&quot; signifies participants evaluable for this outcome measure. Data for this outcome measure was planned to be collected for Primary cohort only.</population>
        <group_list>
          <group group_id="O1">
            <title>Primary Cohort: RSVpreF 60 mcg + Al(OH)3 + SIIV</title>
            <description>Participants were administered an intramuscular dose of respiratory syncytial virus stabilized prefusion F subunit (RSVpreF) 60 microgram (mcg) with aluminum hydroxide (Al[OH]3) by injecting 0.5 milliliter (mL) dose along with single 0.5mL intramuscular dose of SIIV on Day 1. Participants were followed-up through Month 12.</description>
          </group>
          <group group_id="O2">
            <title>Primary Cohort: RSVpreF 60 mcg + CpG/Al(OH)3 + SIIV</title>
            <description>Participants were administered an intramuscular dose of RSVpreF 60 mcg with CpG/Al(OH)3 as 0.5-mL injection along with single 0.5 mL intramuscular dose of SIIV on Day 1. Participants were followed-up through Month 12.</description>
          </group>
          <group group_id="O3">
            <title>Primary Cohort: RSVpreF 120 mcg + Al(OH)3 + SIIV</title>
            <description>Participants were administered an intramuscular dose of RSVpreF 120 mcg with Al(OH)3 as 0.5-mL injection along with single 0.5 mL intramuscular dose of SIIV on Day 1. Participants were followed-up through Month 12.</description>
          </group>
          <group group_id="O4">
            <title>Primary Cohort: RSVpreF 120 mcg + CpG/Al(OH)3 + SIIV</title>
            <description>Participants were administered an intramuscular dose of RSVpreF 120 mcg with CpG/Al(OH)3 as 0.5-mL injection along with single 0.5 mL intramuscular dose of SIIV on Day 1. Participants were followed-up through Month 12.</description>
          </group>
          <group group_id="O5">
            <title>Primary Cohort: RSVpreF 240 mcg + Al(OH)3 + SIIV</title>
            <description>Participants were administered an intramuscular dose of RSVpreF 240 mcg with Al(OH)3 as 0.5-mL injection along with single 0.5 mL intramuscular dose of SIIV on Day 1. Participants were followed-up through Month 12.</description>
          </group>
          <group group_id="O6">
            <title>Primary Cohort: RSVpreF 240 mcg + CpG/Al(OH)3 + SIIV</title>
            <description>Participants were administered an intramuscular dose of RSVpreF 240 mcg with CpG/Al(OH)3 as 0.5-mL injection along with single 0.5 mL intramuscular dose of SIIV on Day 1. Participants were followed-up through Month 12.</description>
          </group>
          <group group_id="O7">
            <title>Primary Cohort: RSVpreF 240 mcg + SIIV</title>
            <description>Participants were administered an intramuscular dose of RSVpreF 240 mcg as 0.5-mL injection along with single 0.5 mL intramuscular dose of SIIV on Day 1. Participants were followed-up through Month 12.</description>
          </group>
          <group group_id="O8">
            <title>Primary Cohort: Placebo + SIIV</title>
            <description>Participants were administered an intramuscular dose of placebo intramuscularly as 0.5-mL injection along with single 0.5 mL intramuscular dose of SIIV on Day 1. Participants were followed-up through Month 12.</description>
          </group>
        </group_list>
        <measure>
          <title>Primary Cohort: Percentage of Participants With Local Reactions Within 14 Days After Vaccination 1</title>
          <description>Local reactions included redness, swelling, and pain at the injection site (left arm) recorded by participants in an electronic diary (e-diary). Redness and swelling were measured and recorded in measuring device units (range: 1 to 20, and greater than [&gt;] 21). 1 measuring device unit = 0.5 centimeter (cm) and graded as: mild (2.5 to 5.0 cm), moderate (greater than [&gt;] 5.0 to 10.0 cm), and severe (&gt;10 cm). Pain at injection site was graded as: mild (did not interfere with activity), moderate (interferes with activity) and severe (prevented daily activity).</description>
          <population>Safety population included all participants who received at least 1 dose of the investigational products (RSVpreF or placebo) at Visit 1. Here, &quot;Overall Number of Participants Analyzed&quot; signifies participants evaluable for this outcome measure. Data for this outcome measure was planned to be collected for Primary cohort only.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="32"/>
                <count group_id="O3" value="32"/>
                <count group_id="O4" value="31"/>
                <count group_id="O5" value="31"/>
                <count group_id="O6" value="30"/>
                <count group_id="O7" value="32"/>
                <count group_id="O8" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pain at Injection Site: Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.3" lower_limit="16.7" upper_limit="51.4"/>
                    <measurement group_id="O2" value="28.1" lower_limit="13.7" upper_limit="46.7"/>
                    <measurement group_id="O3" value="3.1" lower_limit="0.1" upper_limit="16.2"/>
                    <measurement group_id="O4" value="25.8" lower_limit="11.9" upper_limit="44.6"/>
                    <measurement group_id="O5" value="22.6" lower_limit="9.6" upper_limit="41.1"/>
                    <measurement group_id="O6" value="16.7" lower_limit="5.6" upper_limit="34.7"/>
                    <measurement group_id="O7" value="18.8" lower_limit="7.2" upper_limit="36.4"/>
                    <measurement group_id="O8" value="6.7" lower_limit="0.8" upper_limit="22.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain at Injection Site: Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0.0" upper_limit="11.2"/>
                    <measurement group_id="O2" value="3.1" lower_limit="0.1" upper_limit="16.2"/>
                    <measurement group_id="O3" value="0" lower_limit="0.0" upper_limit="10.9"/>
                    <measurement group_id="O4" value="3.2" lower_limit="0.1" upper_limit="16.7"/>
                    <measurement group_id="O5" value="0" lower_limit="0.0" upper_limit="11.2"/>
                    <measurement group_id="O6" value="0" lower_limit="0.0" upper_limit="11.6"/>
                    <measurement group_id="O7" value="0" lower_limit="0.0" upper_limit="10.9"/>
                    <measurement group_id="O8" value="3.3" lower_limit="0.1" upper_limit="17.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain at Injection Site: Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0.0" upper_limit="11.2"/>
                    <measurement group_id="O2" value="0" lower_limit="0.0" upper_limit="10.9"/>
                    <measurement group_id="O3" value="0" lower_limit="0.0" upper_limit="10.9"/>
                    <measurement group_id="O4" value="0" lower_limit="0.0" upper_limit="11.2"/>
                    <measurement group_id="O5" value="0" lower_limit="0.0" upper_limit="11.2"/>
                    <measurement group_id="O6" value="0" lower_limit="0.0" upper_limit="11.6"/>
                    <measurement group_id="O7" value="0" lower_limit="0.0" upper_limit="10.9"/>
                    <measurement group_id="O8" value="0" lower_limit="0.0" upper_limit="11.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness: Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.2" lower_limit="0.1" upper_limit="16.7"/>
                    <measurement group_id="O2" value="0" lower_limit="0.0" upper_limit="10.9"/>
                    <measurement group_id="O3" value="3.1" lower_limit="0.1" upper_limit="16.2"/>
                    <measurement group_id="O4" value="0" lower_limit="0.0" upper_limit="11.2"/>
                    <measurement group_id="O5" value="3.2" lower_limit="0.1" upper_limit="16.7"/>
                    <measurement group_id="O6" value="0" lower_limit="0.0" upper_limit="11.6"/>
                    <measurement group_id="O7" value="3.1" lower_limit="0.1" upper_limit="16.2"/>
                    <measurement group_id="O8" value="0" lower_limit="0.0" upper_limit="11.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness: Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.2" lower_limit="0.1" upper_limit="16.7"/>
                    <measurement group_id="O2" value="0" lower_limit="0.0" upper_limit="10.9"/>
                    <measurement group_id="O3" value="0" lower_limit="0.0" upper_limit="10.9"/>
                    <measurement group_id="O4" value="0" lower_limit="0.0" upper_limit="11.2"/>
                    <measurement group_id="O5" value="3.2" lower_limit="0.1" upper_limit="16.7"/>
                    <measurement group_id="O6" value="0" lower_limit="0.0" upper_limit="11.6"/>
                    <measurement group_id="O7" value="3.1" lower_limit="0.1" upper_limit="16.2"/>
                    <measurement group_id="O8" value="0" lower_limit="0.0" upper_limit="11.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness: Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0.0" upper_limit="11.2"/>
                    <measurement group_id="O2" value="0" lower_limit="0.0" upper_limit="10.9"/>
                    <measurement group_id="O3" value="0" lower_limit="0.0" upper_limit="10.9"/>
                    <measurement group_id="O4" value="0" lower_limit="0.0" upper_limit="11.2"/>
                    <measurement group_id="O5" value="3.2" lower_limit="0.1" upper_limit="16.7"/>
                    <measurement group_id="O6" value="0" lower_limit="0.0" upper_limit="11.6"/>
                    <measurement group_id="O7" value="0" lower_limit="0.0" upper_limit="10.9"/>
                    <measurement group_id="O8" value="0" lower_limit="0.0" upper_limit="11.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling: Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.2" lower_limit="0.1" upper_limit="16.7"/>
                    <measurement group_id="O2" value="3.1" lower_limit="0.1" upper_limit="16.2"/>
                    <measurement group_id="O3" value="3.1" lower_limit="0.1" upper_limit="16.2"/>
                    <measurement group_id="O4" value="0" lower_limit="0.0" upper_limit="11.2"/>
                    <measurement group_id="O5" value="3.2" lower_limit="0.1" upper_limit="16.7"/>
                    <measurement group_id="O6" value="0" lower_limit="0.0" upper_limit="11.6"/>
                    <measurement group_id="O7" value="0" lower_limit="0.0" upper_limit="10.9"/>
                    <measurement group_id="O8" value="3.3" lower_limit="0.1" upper_limit="17.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling: Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0.0" upper_limit="11.2"/>
                    <measurement group_id="O2" value="0" lower_limit="0.0" upper_limit="10.9"/>
                    <measurement group_id="O3" value="0" lower_limit="0.0" upper_limit="10.9"/>
                    <measurement group_id="O4" value="3.2" lower_limit="0.1" upper_limit="16.7"/>
                    <measurement group_id="O5" value="0" lower_limit="0.0" upper_limit="11.2"/>
                    <measurement group_id="O6" value="0" lower_limit="0.0" upper_limit="11.6"/>
                    <measurement group_id="O7" value="0" lower_limit="0.0" upper_limit="10.9"/>
                    <measurement group_id="O8" value="0" lower_limit="0.0" upper_limit="11.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling: Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0.0" upper_limit="11.2"/>
                    <measurement group_id="O2" value="0" lower_limit="0.0" upper_limit="10.9"/>
                    <measurement group_id="O3" value="0" lower_limit="0.0" upper_limit="10.9"/>
                    <measurement group_id="O4" value="0" lower_limit="0.0" upper_limit="11.2"/>
                    <measurement group_id="O5" value="0" lower_limit="0.0" upper_limit="11.2"/>
                    <measurement group_id="O6" value="0" lower_limit="0.0" upper_limit="11.6"/>
                    <measurement group_id="O7" value="0" lower_limit="0.0" upper_limit="10.9"/>
                    <measurement group_id="O8" value="0" lower_limit="0.0" upper_limit="11.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Primary Cohort: Percentage of Participants With Systemic Events Within 14 Days After Vaccination 1</title>
        <description>Systemic events included fever, fatigue/tiredness, headache, vomiting, nausea, diarrhea, muscle pain and joint pain recorded by participants in an e-diary. Fever was graded as: mild (38.0 to 38.4 degrees [deg] Celsius [C]), moderate (38.5 to 38.9 deg C), severe (39 deg C to 40.0 deg C) and grade 4 (&gt;40.0 deg C). Fatigue, headache, nausea, muscle and joint pain were graded as: mild (did not interfere with activity), moderate (some interference with activity) and severe (prevented daily routine activity). Vomiting was graded as: mild (1-2 times in 24 hours [h]), moderate (&gt;2 times in 24h) and severe (required intravenous hydration). Diarrhea was graded as: mild (2-3 loose stools in 24h), moderate (4-5 loose stools in 24h) and severe (6 or more loose stools in 24h).</description>
        <time_frame>Within 14 days after Vaccination 1</time_frame>
        <population>Safety population included all participants who received at least 1 dose of the investigational products (RSVpreF or placebo) at Visit 1. Here, &quot;Overall Number of Participants Analyzed&quot; signifies participants evaluable for this outcome measure. Data for this outcome measure was planned to be collected for Primary cohort only.</population>
        <group_list>
          <group group_id="O1">
            <title>Primary Cohort: RSVpreF 60 mcg + Al(OH)3 + SIIV</title>
            <description>Participants were administered an intramuscular dose of respiratory syncytial virus stabilized prefusion F subunit (RSVpreF) 60 microgram (mcg) with aluminum hydroxide (Al[OH]3) by injecting 0.5 milliliter (mL) dose along with single 0.5mL intramuscular dose of SIIV on Day 1. Participants were followed-up through Month 12.</description>
          </group>
          <group group_id="O2">
            <title>Primary Cohort: RSVpreF 60 mcg + CpG/Al(OH)3 + SIIV</title>
            <description>Participants were administered an intramuscular dose of RSVpreF 60 mcg with CpG/Al(OH)3 as 0.5-mL injection along with single 0.5 mL intramuscular dose of SIIV on Day 1. Participants were followed-up through Month 12.</description>
          </group>
          <group group_id="O3">
            <title>Primary Cohort: RSVpreF 120 mcg + Al(OH)3 + SIIV</title>
            <description>Participants were administered an intramuscular dose of RSVpreF 120 mcg with Al(OH)3 as 0.5-mL injection along with single 0.5 mL intramuscular dose of SIIV on Day 1. Participants were followed-up through Month 12.</description>
          </group>
          <group group_id="O4">
            <title>Primary Cohort: RSVpreF 120 mcg + CpG/Al(OH)3 + SIIV</title>
            <description>Participants were administered an intramuscular dose of RSVpreF 120 mcg with CpG/Al(OH)3 as 0.5-mL injection along with single 0.5 mL intramuscular dose of SIIV on Day 1. Participants were followed-up through Month 12.</description>
          </group>
          <group group_id="O5">
            <title>Primary Cohort: RSVpreF 240 mcg + Al(OH)3 + SIIV</title>
            <description>Participants were administered an intramuscular dose of RSVpreF 240 mcg with Al(OH)3 as 0.5-mL injection along with single 0.5 mL intramuscular dose of SIIV on Day 1. Participants were followed-up through Month 12.</description>
          </group>
          <group group_id="O6">
            <title>Primary Cohort: RSVpreF 240 mcg + CpG/Al(OH)3 + SIIV</title>
            <description>Participants were administered an intramuscular dose of RSVpreF 240 mcg with CpG/Al(OH)3 as 0.5-mL injection along with single 0.5 mL intramuscular dose of SIIV on Day 1. Participants were followed-up through Month 12.</description>
          </group>
          <group group_id="O7">
            <title>Primary Cohort: RSVpreF 240 mcg + SIIV</title>
            <description>Participants were administered an intramuscular dose of RSVpreF 240 mcg as 0.5-mL injection along with single 0.5 mL intramuscular dose of SIIV on Day 1. Participants were followed-up through Month 12.</description>
          </group>
          <group group_id="O8">
            <title>Primary Cohort: Placebo + SIIV</title>
            <description>Participants were administered an intramuscular dose of placebo intramuscularly as 0.5-mL injection along with single 0.5 mL intramuscular dose of SIIV on Day 1. Participants were followed-up through Month 12.</description>
          </group>
        </group_list>
        <measure>
          <title>Primary Cohort: Percentage of Participants With Systemic Events Within 14 Days After Vaccination 1</title>
          <description>Systemic events included fever, fatigue/tiredness, headache, vomiting, nausea, diarrhea, muscle pain and joint pain recorded by participants in an e-diary. Fever was graded as: mild (38.0 to 38.4 degrees [deg] Celsius [C]), moderate (38.5 to 38.9 deg C), severe (39 deg C to 40.0 deg C) and grade 4 (&gt;40.0 deg C). Fatigue, headache, nausea, muscle and joint pain were graded as: mild (did not interfere with activity), moderate (some interference with activity) and severe (prevented daily routine activity). Vomiting was graded as: mild (1-2 times in 24 hours [h]), moderate (&gt;2 times in 24h) and severe (required intravenous hydration). Diarrhea was graded as: mild (2-3 loose stools in 24h), moderate (4-5 loose stools in 24h) and severe (6 or more loose stools in 24h).</description>
          <population>Safety population included all participants who received at least 1 dose of the investigational products (RSVpreF or placebo) at Visit 1. Here, &quot;Overall Number of Participants Analyzed&quot; signifies participants evaluable for this outcome measure. Data for this outcome measure was planned to be collected for Primary cohort only.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="32"/>
                <count group_id="O3" value="32"/>
                <count group_id="O4" value="31"/>
                <count group_id="O5" value="31"/>
                <count group_id="O6" value="30"/>
                <count group_id="O7" value="32"/>
                <count group_id="O8" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Fever: Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0.0" upper_limit="11.2"/>
                    <measurement group_id="O2" value="0" lower_limit="0.0" upper_limit="10.9"/>
                    <measurement group_id="O3" value="9.4" lower_limit="2.0" upper_limit="25.0"/>
                    <measurement group_id="O4" value="0" lower_limit="0.0" upper_limit="11.2"/>
                    <measurement group_id="O5" value="0" lower_limit="0.0" upper_limit="11.2"/>
                    <measurement group_id="O6" value="0" lower_limit="0.0" upper_limit="11.6"/>
                    <measurement group_id="O7" value="0" lower_limit="0.0" upper_limit="10.9"/>
                    <measurement group_id="O8" value="0" lower_limit="0.0" upper_limit="11.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever: Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.2" lower_limit="0.1" upper_limit="16.7"/>
                    <measurement group_id="O2" value="0" lower_limit="0.0" upper_limit="10.9"/>
                    <measurement group_id="O3" value="0" lower_limit="0.0" upper_limit="10.9"/>
                    <measurement group_id="O4" value="3.2" lower_limit="0.1" upper_limit="16.7"/>
                    <measurement group_id="O5" value="0" lower_limit="0.0" upper_limit="11.2"/>
                    <measurement group_id="O6" value="0" lower_limit="0.0" upper_limit="11.6"/>
                    <measurement group_id="O7" value="0" lower_limit="0.0" upper_limit="10.9"/>
                    <measurement group_id="O8" value="0" lower_limit="0.0" upper_limit="11.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever: Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0.0" upper_limit="11.2"/>
                    <measurement group_id="O2" value="0" lower_limit="0.0" upper_limit="10.9"/>
                    <measurement group_id="O3" value="0" lower_limit="0.0" upper_limit="10.9"/>
                    <measurement group_id="O4" value="0" lower_limit="0.0" upper_limit="11.2"/>
                    <measurement group_id="O5" value="0" lower_limit="0.0" upper_limit="11.2"/>
                    <measurement group_id="O6" value="0" lower_limit="0.0" upper_limit="11.6"/>
                    <measurement group_id="O7" value="0" lower_limit="0.0" upper_limit="10.9"/>
                    <measurement group_id="O8" value="0" lower_limit="0.0" upper_limit="11.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever: Grade 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0.0" upper_limit="11.2"/>
                    <measurement group_id="O2" value="0" lower_limit="0.0" upper_limit="10.9"/>
                    <measurement group_id="O3" value="0" lower_limit="0.0" upper_limit="10.9"/>
                    <measurement group_id="O4" value="0" lower_limit="0.0" upper_limit="11.2"/>
                    <measurement group_id="O5" value="0" lower_limit="0.0" upper_limit="11.2"/>
                    <measurement group_id="O6" value="0" lower_limit="0.0" upper_limit="11.6"/>
                    <measurement group_id="O7" value="0" lower_limit="0.0" upper_limit="10.9"/>
                    <measurement group_id="O8" value="0" lower_limit="0.0" upper_limit="11.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nausea: Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.7" lower_limit="2.0" upper_limit="25.8"/>
                    <measurement group_id="O2" value="3.1" lower_limit="0.1" upper_limit="16.2"/>
                    <measurement group_id="O3" value="3.1" lower_limit="0.1" upper_limit="16.2"/>
                    <measurement group_id="O4" value="0" lower_limit="0.0" upper_limit="11.2"/>
                    <measurement group_id="O5" value="6.5" lower_limit="0.8" upper_limit="21.4"/>
                    <measurement group_id="O6" value="0" lower_limit="0.0" upper_limit="11.6"/>
                    <measurement group_id="O7" value="6.3" lower_limit="0.8" upper_limit="20.8"/>
                    <measurement group_id="O8" value="10.0" lower_limit="2.1" upper_limit="26.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nausea: Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0.0" upper_limit="11.2"/>
                    <measurement group_id="O2" value="0" lower_limit="0.0" upper_limit="10.9"/>
                    <measurement group_id="O3" value="0" lower_limit="0.0" upper_limit="10.9"/>
                    <measurement group_id="O4" value="6.5" lower_limit="0.8" upper_limit="21.4"/>
                    <measurement group_id="O5" value="3.2" lower_limit="0.1" upper_limit="16.7"/>
                    <measurement group_id="O6" value="0" lower_limit="0.0" upper_limit="11.6"/>
                    <measurement group_id="O7" value="0" lower_limit="0.0" upper_limit="10.9"/>
                    <measurement group_id="O8" value="0" lower_limit="0.0" upper_limit="11.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nausea: Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0.0" upper_limit="11.2"/>
                    <measurement group_id="O2" value="0" lower_limit="0.0" upper_limit="10.9"/>
                    <measurement group_id="O3" value="0" lower_limit="0.0" upper_limit="10.9"/>
                    <measurement group_id="O4" value="0" lower_limit="0.0" upper_limit="11.2"/>
                    <measurement group_id="O5" value="0" lower_limit="0.0" upper_limit="11.2"/>
                    <measurement group_id="O6" value="0" lower_limit="0.0" upper_limit="11.6"/>
                    <measurement group_id="O7" value="0" lower_limit="0.0" upper_limit="10.9"/>
                    <measurement group_id="O8" value="0" lower_limit="0.0" upper_limit="11.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting: Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0.0" upper_limit="11.2"/>
                    <measurement group_id="O2" value="0" lower_limit="0.0" upper_limit="10.9"/>
                    <measurement group_id="O3" value="0" lower_limit="0.0" upper_limit="10.9"/>
                    <measurement group_id="O4" value="0" lower_limit="0.0" upper_limit="11.2"/>
                    <measurement group_id="O5" value="0" lower_limit="0.0" upper_limit="11.2"/>
                    <measurement group_id="O6" value="0" lower_limit="0.0" upper_limit="11.6"/>
                    <measurement group_id="O7" value="0" lower_limit="0.0" upper_limit="10.9"/>
                    <measurement group_id="O8" value="0" lower_limit="0.0" upper_limit="11.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting: Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0.0" upper_limit="11.2"/>
                    <measurement group_id="O2" value="0" lower_limit="0.0" upper_limit="10.9"/>
                    <measurement group_id="O3" value="0" lower_limit="0.0" upper_limit="10.9"/>
                    <measurement group_id="O4" value="0" lower_limit="0.0" upper_limit="11.2"/>
                    <measurement group_id="O5" value="0" lower_limit="0.0" upper_limit="11.2"/>
                    <measurement group_id="O6" value="0" lower_limit="0.0" upper_limit="11.6"/>
                    <measurement group_id="O7" value="0" lower_limit="0.0" upper_limit="10.9"/>
                    <measurement group_id="O8" value="0" lower_limit="0.0" upper_limit="11.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting: Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0.0" upper_limit="11.2"/>
                    <measurement group_id="O2" value="0" lower_limit="0.0" upper_limit="10.9"/>
                    <measurement group_id="O3" value="0" lower_limit="0.0" upper_limit="10.9"/>
                    <measurement group_id="O4" value="0" lower_limit="0.0" upper_limit="11.2"/>
                    <measurement group_id="O5" value="0" lower_limit="0.0" upper_limit="11.2"/>
                    <measurement group_id="O6" value="0" lower_limit="0.0" upper_limit="11.6"/>
                    <measurement group_id="O7" value="0" lower_limit="0.0" upper_limit="10.9"/>
                    <measurement group_id="O8" value="00" lower_limit="0.0" upper_limit="11.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea: Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.7" lower_limit="2.0" upper_limit="25.8"/>
                    <measurement group_id="O2" value="3.1" lower_limit="0.1" upper_limit="16.2"/>
                    <measurement group_id="O3" value="9.4" lower_limit="2.0" upper_limit="25.0"/>
                    <measurement group_id="O4" value="3.2" lower_limit="0.1" upper_limit="16.7"/>
                    <measurement group_id="O5" value="0" lower_limit="0.0" upper_limit="11.2"/>
                    <measurement group_id="O6" value="10.0" lower_limit="2.1" upper_limit="26.5"/>
                    <measurement group_id="O7" value="6.3" lower_limit="0.8" upper_limit="20.8"/>
                    <measurement group_id="O8" value="6.7" lower_limit="0.8" upper_limit="22.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea: Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.2" lower_limit="0.1" upper_limit="16.7"/>
                    <measurement group_id="O2" value="3.1" lower_limit="0.1" upper_limit="16.2"/>
                    <measurement group_id="O3" value="6.3" lower_limit="0.8" upper_limit="20.8"/>
                    <measurement group_id="O4" value="3.2" lower_limit="0.1" upper_limit="16.7"/>
                    <measurement group_id="O5" value="3.2" lower_limit="0.1" upper_limit="16.7"/>
                    <measurement group_id="O6" value="0" lower_limit="0.0" upper_limit="11.6"/>
                    <measurement group_id="O7" value="0" lower_limit="0.0" upper_limit="10.9"/>
                    <measurement group_id="O8" value="6.7" lower_limit="0.8" upper_limit="22.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea: Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0.0" upper_limit="11.2"/>
                    <measurement group_id="O2" value="0" lower_limit="0.0" upper_limit="10.9"/>
                    <measurement group_id="O3" value="0" lower_limit="0.0" upper_limit="10.9"/>
                    <measurement group_id="O4" value="0" lower_limit="0.0" upper_limit="11.2"/>
                    <measurement group_id="O5" value="0" lower_limit="0.0" upper_limit="11.2"/>
                    <measurement group_id="O6" value="0" lower_limit="0.0" upper_limit="11.6"/>
                    <measurement group_id="O7" value="0" lower_limit="0.0" upper_limit="10.9"/>
                    <measurement group_id="O8" value="0" lower_limit="0.0" upper_limit="11.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache: Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.1" lower_limit="5.5" upper_limit="33.7"/>
                    <measurement group_id="O2" value="3.1" lower_limit="0.1" upper_limit="16.2"/>
                    <measurement group_id="O3" value="3.1" lower_limit="0.1" upper_limit="16.2"/>
                    <measurement group_id="O4" value="6.5" lower_limit="0.8" upper_limit="21.4"/>
                    <measurement group_id="O5" value="3.2" lower_limit="0.1" upper_limit="16.7"/>
                    <measurement group_id="O6" value="16.7" lower_limit="5.6" upper_limit="34.7"/>
                    <measurement group_id="O7" value="25.0" lower_limit="11.5" upper_limit="43.4"/>
                    <measurement group_id="O8" value="6.7" lower_limit="0.8" upper_limit="22.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache: Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.2" lower_limit="0.1" upper_limit="16.7"/>
                    <measurement group_id="O2" value="6.3" lower_limit="0.8" upper_limit="20.8"/>
                    <measurement group_id="O3" value="0" lower_limit="0.0" upper_limit="10.9"/>
                    <measurement group_id="O4" value="9.7" lower_limit="2.0" upper_limit="25.8"/>
                    <measurement group_id="O5" value="3.2" lower_limit="0.1" upper_limit="16.7"/>
                    <measurement group_id="O6" value="0" lower_limit="0.0" upper_limit="11.6"/>
                    <measurement group_id="O7" value="9.4" lower_limit="2.0" upper_limit="25.0"/>
                    <measurement group_id="O8" value="0" lower_limit="0.0" upper_limit="11.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache: Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0.0" upper_limit="11.2"/>
                    <measurement group_id="O2" value="0" lower_limit="0.0" upper_limit="10.9"/>
                    <measurement group_id="O3" value="0" lower_limit="0.0" upper_limit="10.9"/>
                    <measurement group_id="O4" value="3.2" lower_limit="0.1" upper_limit="16.7"/>
                    <measurement group_id="O5" value="0" lower_limit="0.0" upper_limit="11.2"/>
                    <measurement group_id="O6" value="0" lower_limit="0.0" upper_limit="11.6"/>
                    <measurement group_id="O7" value="3.1" lower_limit="0.1" upper_limit="16.2"/>
                    <measurement group_id="O8" value="0" lower_limit="0.0" upper_limit="11.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FatigueTtiredness: Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.1" lower_limit="5.5" upper_limit="33.7"/>
                    <measurement group_id="O2" value="15.6" lower_limit="5.3" upper_limit="32.8"/>
                    <measurement group_id="O3" value="9.4" lower_limit="2.0" upper_limit="25.0"/>
                    <measurement group_id="O4" value="3.2" lower_limit="0.1" upper_limit="16.7"/>
                    <measurement group_id="O5" value="16.1" lower_limit="5.5" upper_limit="33.7"/>
                    <measurement group_id="O6" value="3.3" lower_limit="0.1" upper_limit="17.2"/>
                    <measurement group_id="O7" value="31.3" lower_limit="16.1" upper_limit="50.0"/>
                    <measurement group_id="O8" value="16.7" lower_limit="5.6" upper_limit="34.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue/Tiredness: Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.5" lower_limit="0.8" upper_limit="21.4"/>
                    <measurement group_id="O2" value="3.1" lower_limit="0.1" upper_limit="16.2"/>
                    <measurement group_id="O3" value="18.8" lower_limit="7.2" upper_limit="36.4"/>
                    <measurement group_id="O4" value="25.8" lower_limit="11.9" upper_limit="44.6"/>
                    <measurement group_id="O5" value="3.2" lower_limit="0.1" upper_limit="16.7"/>
                    <measurement group_id="O6" value="10.0" lower_limit="2.1" upper_limit="26.5"/>
                    <measurement group_id="O7" value="9.4" lower_limit="2.0" upper_limit="25.0"/>
                    <measurement group_id="O8" value="3.3" lower_limit="0.1" upper_limit="17.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue/Tiredness: Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0.0" upper_limit="11.2"/>
                    <measurement group_id="O2" value="0" lower_limit="0.0" upper_limit="10.9"/>
                    <measurement group_id="O3" value="0" lower_limit="0.0" upper_limit="10.9"/>
                    <measurement group_id="O4" value="0" lower_limit="0.0" upper_limit="11.2"/>
                    <measurement group_id="O5" value="0" lower_limit="0.0" upper_limit="11.2"/>
                    <measurement group_id="O6" value="0" lower_limit="0.0" upper_limit="11.6"/>
                    <measurement group_id="O7" value="3.1" lower_limit="0.1" upper_limit="16.2"/>
                    <measurement group_id="O8" value="0" lower_limit="0.0" upper_limit="11.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Muscle Pain: Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.7" lower_limit="2.0" upper_limit="25.8"/>
                    <measurement group_id="O2" value="6.3" lower_limit="0.8" upper_limit="20.8"/>
                    <measurement group_id="O3" value="6.3" lower_limit="0.8" upper_limit="20.8"/>
                    <measurement group_id="O4" value="9.7" lower_limit="2.0" upper_limit="25.8"/>
                    <measurement group_id="O5" value="12.9" lower_limit="3.6" upper_limit="29.8"/>
                    <measurement group_id="O6" value="10.0" lower_limit="2.1" upper_limit="26.5"/>
                    <measurement group_id="O7" value="12.5" lower_limit="3.5" upper_limit="29.0"/>
                    <measurement group_id="O8" value="16.7" lower_limit="5.6" upper_limit="34.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Muscle Pain: Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0.0" upper_limit="11.2"/>
                    <measurement group_id="O2" value="3.1" lower_limit="0.1" upper_limit="16.2"/>
                    <measurement group_id="O3" value="3.1" lower_limit="0.1" upper_limit="16.2"/>
                    <measurement group_id="O4" value="3.2" lower_limit="0.1" upper_limit="16.7"/>
                    <measurement group_id="O5" value="3.2" lower_limit="0.1" upper_limit="16.7"/>
                    <measurement group_id="O6" value="6.7" lower_limit="0.8" upper_limit="22.1"/>
                    <measurement group_id="O7" value="6.3" lower_limit="0.8" upper_limit="20.8"/>
                    <measurement group_id="O8" value="3.3" lower_limit="0.1" upper_limit="17.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Muscle Pain: Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0.0" upper_limit="11.2"/>
                    <measurement group_id="O2" value="0" lower_limit="0.0" upper_limit="10.9"/>
                    <measurement group_id="O3" value="0" lower_limit="0.0" upper_limit="10.9"/>
                    <measurement group_id="O4" value="0" lower_limit="0.0" upper_limit="11.2"/>
                    <measurement group_id="O5" value="0" lower_limit="0.0" upper_limit="11.2"/>
                    <measurement group_id="O6" value="0" lower_limit="0.0" upper_limit="11.6"/>
                    <measurement group_id="O7" value="0" lower_limit="0.0" upper_limit="10.9"/>
                    <measurement group_id="O8" value="0" lower_limit="0.0" upper_limit="11.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Joint Pain: Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.2" lower_limit="0.1" upper_limit="16.7"/>
                    <measurement group_id="O2" value="0" lower_limit="0.0" upper_limit="10.9"/>
                    <measurement group_id="O3" value="6.3" lower_limit="0.8" upper_limit="20.8"/>
                    <measurement group_id="O4" value="3.2" lower_limit="0.1" upper_limit="16.7"/>
                    <measurement group_id="O5" value="0" lower_limit="0.0" upper_limit="11.2"/>
                    <measurement group_id="O6" value="6.7" lower_limit="0.8" upper_limit="22.1"/>
                    <measurement group_id="O7" value="9.4" lower_limit="2.0" upper_limit="25.0"/>
                    <measurement group_id="O8" value="10.0" lower_limit="2.1" upper_limit="26.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Joint Pain: Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0.0" upper_limit="11.2"/>
                    <measurement group_id="O2" value="3.1" lower_limit="0.1" upper_limit="16.2"/>
                    <measurement group_id="O3" value="9.4" lower_limit="2.0" upper_limit="25.0"/>
                    <measurement group_id="O4" value="3.2" lower_limit="0.1" upper_limit="16.7"/>
                    <measurement group_id="O5" value="0" lower_limit="0.0" upper_limit="11.2"/>
                    <measurement group_id="O6" value="0" lower_limit="0.0" upper_limit="11.6"/>
                    <measurement group_id="O7" value="0" lower_limit="0.0" upper_limit="10.9"/>
                    <measurement group_id="O8" value="3.3" lower_limit="0.1" upper_limit="17.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Joint Pain: Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0.0" upper_limit="11.2"/>
                    <measurement group_id="O2" value="0" lower_limit="0.0" upper_limit="10.9"/>
                    <measurement group_id="O3" value="0" lower_limit="0.0" upper_limit="10.9"/>
                    <measurement group_id="O4" value="0" lower_limit="0.0" upper_limit="11.2"/>
                    <measurement group_id="O5" value="0" lower_limit="0.0" upper_limit="11.2"/>
                    <measurement group_id="O6" value="0" lower_limit="0.0" upper_limit="11.6"/>
                    <measurement group_id="O7" value="0" lower_limit="0.0" upper_limit="10.9"/>
                    <measurement group_id="O8" value="0" lower_limit="0.0" upper_limit="11.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Primary Cohort: Percentage of Participants With Adverse Events (AEs) Within 1 Month After Vaccination 1</title>
        <description>An AE is any untoward medical occurrence in a study participant administered a product or medical device; the event need not necessarily have a causal relationship with the treatment or usage. AEs included both serious and non-serious adverse events.</description>
        <time_frame>Within 1 month after Vaccination 1</time_frame>
        <population>Safety population included all participants who received at least 1 dose of the investigational products (RSVpreF or placebo) at Visit 1. Data for this outcome measure was planned to be collected for Primary cohort only.</population>
        <group_list>
          <group group_id="O1">
            <title>Primary Cohort: RSVpreF 60 mcg + Al(OH)3 + SIIV</title>
            <description>Participants were administered an intramuscular dose of respiratory syncytial virus stabilized prefusion F subunit (RSVpreF) 60 microgram (mcg) with aluminum hydroxide (Al[OH]3) by injecting 0.5 milliliter (mL) dose along with single 0.5mL intramuscular dose of SIIV on Day 1. Participants were followed-up through Month 12.</description>
          </group>
          <group group_id="O2">
            <title>Primary Cohort: RSVpreF 60 mcg + CpG/Al(OH)3 + SIIV</title>
            <description>Participants were administered an intramuscular dose of RSVpreF 60 mcg with CpG/Al(OH)3 as 0.5-mL injection along with single 0.5 mL intramuscular dose of SIIV on Day 1. Participants were followed-up through Month 12.</description>
          </group>
          <group group_id="O3">
            <title>Primary Cohort: RSVpreF 120 mcg + Al(OH)3 + SIIV</title>
            <description>Participants were administered an intramuscular dose of RSVpreF 120 mcg with Al(OH)3 as 0.5-mL injection along with single 0.5 mL intramuscular dose of SIIV on Day 1. Participants were followed-up through Month 12.</description>
          </group>
          <group group_id="O4">
            <title>Primary Cohort: RSVpreF 120 mcg + CpG/Al(OH)3 + SIIV</title>
            <description>Participants were administered an intramuscular dose of RSVpreF 120 mcg with CpG/Al(OH)3 as 0.5-mL injection along with single 0.5 mL intramuscular dose of SIIV on Day 1. Participants were followed-up through Month 12.</description>
          </group>
          <group group_id="O5">
            <title>Primary Cohort: RSVpreF 240 mcg + Al(OH)3 + SIIV</title>
            <description>Participants were administered an intramuscular dose of RSVpreF 240 mcg with Al(OH)3 as 0.5-mL injection along with single 0.5 mL intramuscular dose of SIIV on Day 1. Participants were followed-up through Month 12.</description>
          </group>
          <group group_id="O6">
            <title>Primary Cohort: RSVpreF 240 mcg + CpG/Al(OH)3 + SIIV</title>
            <description>Participants were administered an intramuscular dose of RSVpreF 240 mcg with CpG/Al(OH)3 as 0.5-mL injection along with single 0.5 mL intramuscular dose of SIIV on Day 1. Participants were followed-up through Month 12.</description>
          </group>
          <group group_id="O7">
            <title>Primary Cohort: RSVpreF 240 mcg + SIIV</title>
            <description>Participants were administered an intramuscular dose of RSVpreF 240 mcg as 0.5-mL injection along with single 0.5 mL intramuscular dose of SIIV on Day 1. Participants were followed-up through Month 12.</description>
          </group>
          <group group_id="O8">
            <title>Primary Cohort: Placebo + SIIV</title>
            <description>Participants were administered an intramuscular dose of placebo intramuscularly as 0.5-mL injection along with single 0.5 mL intramuscular dose of SIIV on Day 1. Participants were followed-up through Month 12.</description>
          </group>
        </group_list>
        <measure>
          <title>Primary Cohort: Percentage of Participants With Adverse Events (AEs) Within 1 Month After Vaccination 1</title>
          <description>An AE is any untoward medical occurrence in a study participant administered a product or medical device; the event need not necessarily have a causal relationship with the treatment or usage. AEs included both serious and non-serious adverse events.</description>
          <population>Safety population included all participants who received at least 1 dose of the investigational products (RSVpreF or placebo) at Visit 1. Data for this outcome measure was planned to be collected for Primary cohort only.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="32"/>
                <count group_id="O3" value="32"/>
                <count group_id="O4" value="31"/>
                <count group_id="O5" value="31"/>
                <count group_id="O6" value="30"/>
                <count group_id="O7" value="32"/>
                <count group_id="O8" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.9" lower_limit="9.3" upper_limit="40.0"/>
                    <measurement group_id="O2" value="21.9" lower_limit="9.3" upper_limit="40.0"/>
                    <measurement group_id="O3" value="34.4" lower_limit="18.6" upper_limit="53.2"/>
                    <measurement group_id="O4" value="29.0" lower_limit="14.2" upper_limit="48.0"/>
                    <measurement group_id="O5" value="25.8" lower_limit="11.9" upper_limit="44.6"/>
                    <measurement group_id="O6" value="23.3" lower_limit="9.9" upper_limit="42.3"/>
                    <measurement group_id="O7" value="21.9" lower_limit="9.3" upper_limit="40.0"/>
                    <measurement group_id="O8" value="16.7" lower_limit="5.6" upper_limit="34.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Primary Cohort: Percentage of Participants With Medically Attended Adverse Events (MAEs) and Serious Adverse Events (SAEs) Through 12 Months After Vaccination 1</title>
        <description>An MAE was defined as a non-serious AE that resulted in an evaluation at a medical facility. A SAE is any untoward medical occurrence at any dose: results in death; is life-threatening (immediate risk of death); requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity (substantial disruption of the ability to conduct normal life functions); results in congenital anomaly/birth defect.</description>
        <time_frame>Up to 12 months after Vaccination 1</time_frame>
        <population>Safety population included all participants who received at least 1 dose of the investigational products (RSVpreF or placebo) at Visit 1. Data for this outcome measure was planned to be collected for Primary cohort only.</population>
        <group_list>
          <group group_id="O1">
            <title>Primary Cohort: RSVpreF 60 mcg + Al(OH)3 + SIIV</title>
            <description>Participants were administered an intramuscular dose of respiratory syncytial virus stabilized prefusion F subunit (RSVpreF) 60 microgram (mcg) with aluminum hydroxide (Al[OH]3) by injecting 0.5 milliliter (mL) dose along with single 0.5mL intramuscular dose of SIIV on Day 1. Participants were followed-up through Month 12.</description>
          </group>
          <group group_id="O2">
            <title>Primary Cohort: RSVpreF 60 mcg + CpG/Al(OH)3 + SIIV</title>
            <description>Participants were administered an intramuscular dose of RSVpreF 60 mcg with CpG/Al(OH)3 as 0.5-mL injection along with single 0.5 mL intramuscular dose of SIIV on Day 1. Participants were followed-up through Month 12.</description>
          </group>
          <group group_id="O3">
            <title>Primary Cohort: RSVpreF 120 mcg + Al(OH)3 + SIIV</title>
            <description>Participants were administered an intramuscular dose of RSVpreF 120 mcg with Al(OH)3 as 0.5-mL injection along with single 0.5 mL intramuscular dose of SIIV on Day 1. Participants were followed-up through Month 12.</description>
          </group>
          <group group_id="O4">
            <title>Primary Cohort: RSVpreF 120 mcg + CpG/Al(OH)3 + SIIV</title>
            <description>Participants were administered an intramuscular dose of RSVpreF 120 mcg with CpG/Al(OH)3 as 0.5-mL injection along with single 0.5 mL intramuscular dose of SIIV on Day 1. Participants were followed-up through Month 12.</description>
          </group>
          <group group_id="O5">
            <title>Primary Cohort: RSVpreF 240 mcg + Al(OH)3 + SIIV</title>
            <description>Participants were administered an intramuscular dose of RSVpreF 240 mcg with Al(OH)3 as 0.5-mL injection along with single 0.5 mL intramuscular dose of SIIV on Day 1. Participants were followed-up through Month 12.</description>
          </group>
          <group group_id="O6">
            <title>Primary Cohort: RSVpreF 240 mcg + CpG/Al(OH)3 + SIIV</title>
            <description>Participants were administered an intramuscular dose of RSVpreF 240 mcg with CpG/Al(OH)3 as 0.5-mL injection along with single 0.5 mL intramuscular dose of SIIV on Day 1. Participants were followed-up through Month 12.</description>
          </group>
          <group group_id="O7">
            <title>Primary Cohort: RSVpreF 240 mcg + SIIV</title>
            <description>Participants were administered an intramuscular dose of RSVpreF 240 mcg as 0.5-mL injection along with single 0.5 mL intramuscular dose of SIIV on Day 1. Participants were followed-up through Month 12.</description>
          </group>
          <group group_id="O8">
            <title>Primary Cohort: Placebo + SIIV</title>
            <description>Participants were administered an intramuscular dose of placebo intramuscularly as 0.5-mL injection along with single 0.5 mL intramuscular dose of SIIV on Day 1. Participants were followed-up through Month 12.</description>
          </group>
        </group_list>
        <measure>
          <title>Primary Cohort: Percentage of Participants With Medically Attended Adverse Events (MAEs) and Serious Adverse Events (SAEs) Through 12 Months After Vaccination 1</title>
          <description>An MAE was defined as a non-serious AE that resulted in an evaluation at a medical facility. A SAE is any untoward medical occurrence at any dose: results in death; is life-threatening (immediate risk of death); requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity (substantial disruption of the ability to conduct normal life functions); results in congenital anomaly/birth defect.</description>
          <population>Safety population included all participants who received at least 1 dose of the investigational products (RSVpreF or placebo) at Visit 1. Data for this outcome measure was planned to be collected for Primary cohort only.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="32"/>
                <count group_id="O3" value="32"/>
                <count group_id="O4" value="31"/>
                <count group_id="O5" value="31"/>
                <count group_id="O6" value="30"/>
                <count group_id="O7" value="32"/>
                <count group_id="O8" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>MAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.9" lower_limit="29.1" upper_limit="65.3"/>
                    <measurement group_id="O2" value="59.4" lower_limit="40.6" upper_limit="76.3"/>
                    <measurement group_id="O3" value="46.9" lower_limit="29.1" upper_limit="65.3"/>
                    <measurement group_id="O4" value="51.6" lower_limit="33.1" upper_limit="69.8"/>
                    <measurement group_id="O5" value="54.8" lower_limit="36.0" upper_limit="72.7"/>
                    <measurement group_id="O6" value="60.0" lower_limit="40.6" upper_limit="77.3"/>
                    <measurement group_id="O7" value="50.0" lower_limit="31.9" upper_limit="68.1"/>
                    <measurement group_id="O8" value="50.0" lower_limit="31.3" upper_limit="68.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.3" lower_limit="0.8" upper_limit="20.8"/>
                    <measurement group_id="O2" value="12.5" lower_limit="3.5" upper_limit="29.0"/>
                    <measurement group_id="O3" value="12.5" lower_limit="3.5" upper_limit="29.0"/>
                    <measurement group_id="O4" value="12.9" lower_limit="3.6" upper_limit="29.8"/>
                    <measurement group_id="O5" value="16.1" lower_limit="5.5" upper_limit="33.7"/>
                    <measurement group_id="O6" value="13.3" lower_limit="3.8" upper_limit="30.7"/>
                    <measurement group_id="O7" value="12.5" lower_limit="3.5" upper_limit="29.0"/>
                    <measurement group_id="O8" value="10.0" lower_limit="2.1" upper_limit="26.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Primary Cohort: Geometric Mean Titers (GMT) of Respiratory Syncytial Virus Subgroup A (RSV A) and Respiratory Syncytial Virus Subgroup B (RSV B) Neutralizing Antibodies Before and 1 Month After Vaccination 1</title>
        <description>GMTs of RSV A and RSV B antigens were measured using neutralizing assay. Titers above the lower limit of quantitation (LLOQ) were considered accurate and their quantitated values were reported. The neutralizing titer LLOQ values were: A = 50 and B = 70. Assay results below the LLOQ were set to 0.5 × LLOQ.</description>
        <time_frame>Before vaccination and 1 Month after Vaccination 1</time_frame>
        <population>Evaluable immunogenicity population: eligible participants who received both SIIV and RSV vaccinations or SIIV and placebo as randomized, had blood drawn within 27-42 days after Visit 1 pre-specified time frames at 1-month post-vaccination follow-up visit, had at least 1 valid, determinate assay result for proposed analysis, had no major protocol violations. Number Analyzed= participants evaluable for each row. Data for this outcome measure was planned to be collected for Primary cohort only.</population>
        <group_list>
          <group group_id="O1">
            <title>Primary Cohort: RSVpreF 60 mcg + Al(OH)3 + SIIV</title>
            <description>Participants were administered an intramuscular dose of respiratory syncytial virus stabilized prefusion F subunit (RSVpreF) 60 microgram (mcg) with aluminum hydroxide (Al[OH]3) by injecting 0.5 milliliter (mL) dose along with single 0.5mL intramuscular dose of SIIV on Day 1. Participants were followed-up through Month 12.</description>
          </group>
          <group group_id="O2">
            <title>Primary Cohort: RSVpreF 60 mcg + CpG/Al(OH)3 + SIIV</title>
            <description>Participants were administered an intramuscular dose of RSVpreF 60 mcg with CpG/Al(OH)3 as 0.5-mL injection along with single 0.5 mL intramuscular dose of SIIV on Day 1. Participants were followed-up through Month 12.</description>
          </group>
          <group group_id="O3">
            <title>Primary Cohort: RSVpreF 120 mcg + Al(OH)3 + SIIV</title>
            <description>Participants were administered an intramuscular dose of RSVpreF 120 mcg with Al(OH)3 as 0.5-mL injection along with single 0.5 mL intramuscular dose of SIIV on Day 1. Participants were followed-up through Month 12.</description>
          </group>
          <group group_id="O4">
            <title>Primary Cohort: RSVpreF 120 mcg + CpG/Al(OH)3 + SIIV</title>
            <description>Participants were administered an intramuscular dose of RSVpreF 120 mcg with CpG/Al(OH)3 as 0.5-mL injection along with single 0.5 mL intramuscular dose of SIIV on Day 1. Participants were followed-up through Month 12.</description>
          </group>
          <group group_id="O5">
            <title>Primary Cohort: RSVpreF 240 mcg + Al(OH)3 + SIIV</title>
            <description>Participants were administered an intramuscular dose of RSVpreF 240 mcg with Al(OH)3 as 0.5-mL injection along with single 0.5 mL intramuscular dose of SIIV on Day 1. Participants were followed-up through Month 12.</description>
          </group>
          <group group_id="O6">
            <title>Primary Cohort: RSVpreF 240 mcg + CpG/Al(OH)3 + SIIV</title>
            <description>Participants were administered an intramuscular dose of RSVpreF 240 mcg with CpG/Al(OH)3 as 0.5-mL injection along with single 0.5 mL intramuscular dose of SIIV on Day 1. Participants were followed-up through Month 12.</description>
          </group>
          <group group_id="O7">
            <title>Primary Cohort: RSVpreF 240 mcg + SIIV</title>
            <description>Participants were administered an intramuscular dose of RSVpreF 240 mcg as 0.5-mL injection along with single 0.5 mL intramuscular dose of SIIV on Day 1. Participants were followed-up through Month 12.</description>
          </group>
          <group group_id="O8">
            <title>Primary Cohort: Placebo + SIIV</title>
            <description>Participants were administered an intramuscular dose of placebo intramuscularly as 0.5-mL injection along with single 0.5 mL intramuscular dose of SIIV on Day 1. Participants were followed-up through Month 12.</description>
          </group>
        </group_list>
        <measure>
          <title>Primary Cohort: Geometric Mean Titers (GMT) of Respiratory Syncytial Virus Subgroup A (RSV A) and Respiratory Syncytial Virus Subgroup B (RSV B) Neutralizing Antibodies Before and 1 Month After Vaccination 1</title>
          <description>GMTs of RSV A and RSV B antigens were measured using neutralizing assay. Titers above the lower limit of quantitation (LLOQ) were considered accurate and their quantitated values were reported. The neutralizing titer LLOQ values were: A = 50 and B = 70. Assay results below the LLOQ were set to 0.5 × LLOQ.</description>
          <population>Evaluable immunogenicity population: eligible participants who received both SIIV and RSV vaccinations or SIIV and placebo as randomized, had blood drawn within 27-42 days after Visit 1 pre-specified time frames at 1-month post-vaccination follow-up visit, had at least 1 valid, determinate assay result for proposed analysis, had no major protocol violations. Number Analyzed= participants evaluable for each row. Data for this outcome measure was planned to be collected for Primary cohort only.</population>
          <units>titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="32"/>
                <count group_id="O3" value="32"/>
                <count group_id="O4" value="31"/>
                <count group_id="O5" value="31"/>
                <count group_id="O6" value="29"/>
                <count group_id="O7" value="31"/>
                <count group_id="O8" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>RSV A: Before Vaccination 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="29"/>
                    <count group_id="O2" value="31"/>
                    <count group_id="O3" value="32"/>
                    <count group_id="O4" value="31"/>
                    <count group_id="O5" value="31"/>
                    <count group_id="O6" value="29"/>
                    <count group_id="O7" value="31"/>
                    <count group_id="O8" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2113" lower_limit="1610.6" upper_limit="2772.5"/>
                    <measurement group_id="O2" value="2592" lower_limit="1932.3" upper_limit="3477.8"/>
                    <measurement group_id="O3" value="2234" lower_limit="1591.1" upper_limit="3136.5"/>
                    <measurement group_id="O4" value="2395" lower_limit="1817.9" upper_limit="3155.4"/>
                    <measurement group_id="O5" value="2333" lower_limit="1779.8" upper_limit="3057.1"/>
                    <measurement group_id="O6" value="2061" lower_limit="1600.2" upper_limit="2653.4"/>
                    <measurement group_id="O7" value="2243" lower_limit="1696.4" upper_limit="2966.8"/>
                    <measurement group_id="O8" value="2093" lower_limit="1509.0" upper_limit="2903.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RSV A: 1 Month After Vaccination 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="29"/>
                    <count group_id="O2" value="32"/>
                    <count group_id="O3" value="32"/>
                    <count group_id="O4" value="31"/>
                    <count group_id="O5" value="31"/>
                    <count group_id="O6" value="29"/>
                    <count group_id="O7" value="31"/>
                    <count group_id="O8" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15158" lower_limit="10503.8" upper_limit="21875.0"/>
                    <measurement group_id="O2" value="12385" lower_limit="9555.6" upper_limit="16051.2"/>
                    <measurement group_id="O3" value="17806" lower_limit="12893.3" upper_limit="24590.4"/>
                    <measurement group_id="O4" value="15492" lower_limit="11012.7" upper_limit="21793.6"/>
                    <measurement group_id="O5" value="18045" lower_limit="12589.5" upper_limit="25865.5"/>
                    <measurement group_id="O6" value="23929" lower_limit="18242.8" upper_limit="31386.8"/>
                    <measurement group_id="O7" value="23833" lower_limit="17799.2" upper_limit="31912.0"/>
                    <measurement group_id="O8" value="1823" lower_limit="1376.5" upper_limit="2415.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RSV B: Before Vaccination 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="29"/>
                    <count group_id="O2" value="31"/>
                    <count group_id="O3" value="32"/>
                    <count group_id="O4" value="31"/>
                    <count group_id="O5" value="31"/>
                    <count group_id="O6" value="29"/>
                    <count group_id="O7" value="31"/>
                    <count group_id="O8" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1786" lower_limit="1383.3" upper_limit="2305.3"/>
                    <measurement group_id="O2" value="2116" lower_limit="1526.7" upper_limit="2933.7"/>
                    <measurement group_id="O3" value="1728" lower_limit="1271.9" upper_limit="2346.4"/>
                    <measurement group_id="O4" value="2021" lower_limit="1451.8" upper_limit="2812.2"/>
                    <measurement group_id="O5" value="1884" lower_limit="1337.0" upper_limit="2655.9"/>
                    <measurement group_id="O6" value="1844" lower_limit="1417.5" upper_limit="2398.8"/>
                    <measurement group_id="O7" value="1580" lower_limit="1210.9" upper_limit="2061.1"/>
                    <measurement group_id="O8" value="1677" lower_limit="1156.2" upper_limit="2433.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RSV B: 1 Month After Vaccination 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="29"/>
                    <count group_id="O2" value="32"/>
                    <count group_id="O3" value="32"/>
                    <count group_id="O4" value="31"/>
                    <count group_id="O5" value="31"/>
                    <count group_id="O6" value="29"/>
                    <count group_id="O7" value="31"/>
                    <count group_id="O8" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15182" lower_limit="9785.1" upper_limit="23555.6"/>
                    <measurement group_id="O2" value="9694" lower_limit="7396.8" upper_limit="12705.8"/>
                    <measurement group_id="O3" value="14436" lower_limit="10196.9" upper_limit="20436.9"/>
                    <measurement group_id="O4" value="12781" lower_limit="8571.0" upper_limit="19058.7"/>
                    <measurement group_id="O5" value="18205" lower_limit="12574.4" upper_limit="26356.6"/>
                    <measurement group_id="O6" value="20777" lower_limit="15034.9" upper_limit="28711.0"/>
                    <measurement group_id="O7" value="22249" lower_limit="15715.7" upper_limit="31497.5"/>
                    <measurement group_id="O8" value="1617" lower_limit="1139.6" upper_limit="2294.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Primary Cohort: Hemagglutination Inhibition Assay (HAI) and Neutralizing Antibody Geometric Mean Titers for All Strains Following the Seasonal Inactivated Influenza Vaccine (SIIV) Before and 1 Month After Vaccination 1</title>
        <description>The HAI and neutralizing titer LLOQ value for each strain was 1:10. Assay results below the LLOQ were set to 0.5 × LLOQ. The analysis was performed on following strains: H1N1 A/Michigan, H3N2 A/Brisbane, B/Phuket for HAI and H3N2/Brisbane for neutralizing assay.</description>
        <time_frame>Before vaccination and 1 Month after Vaccination 1</time_frame>
        <population>Evaluable immunogenicity population: participants who received both SIIV and RSV vaccinations or SIIV and placebo as randomized, had blood drawn within 27-42 days after Visit 1 pre-specified time frames at 1-month post-vaccination follow-up visit, had at least 1 valid, determinate assay result for analysis, had no major protocol violations. Number Analyzed = participants evaluable for each specified row. Data for this outcome was planned to be collected for Primary cohort only.</population>
        <group_list>
          <group group_id="O1">
            <title>Primary Cohort: RSVpreF 60 mcg + Al(OH)3 + SIIV</title>
            <description>Participants were administered an intramuscular dose of respiratory syncytial virus stabilized prefusion F subunit (RSVpreF) 60 microgram (mcg) with aluminum hydroxide (Al[OH]3) by injecting 0.5 milliliter (mL) dose along with single 0.5mL intramuscular dose of SIIV on Day 1. Participants were followed-up through Month 12.</description>
          </group>
          <group group_id="O2">
            <title>Primary Cohort: RSVpreF 60 mcg + CpG/Al(OH)3 + SIIV</title>
            <description>Participants were administered an intramuscular dose of RSVpreF 60 mcg with CpG/Al(OH)3 as 0.5-mL injection along with single 0.5 mL intramuscular dose of SIIV on Day 1. Participants were followed-up through Month 12.</description>
          </group>
          <group group_id="O3">
            <title>Primary Cohort: RSVpreF 120 mcg + Al(OH)3 + SIIV</title>
            <description>Participants were administered an intramuscular dose of RSVpreF 120 mcg with Al(OH)3 as 0.5-mL injection along with single 0.5 mL intramuscular dose of SIIV on Day 1. Participants were followed-up through Month 12.</description>
          </group>
          <group group_id="O4">
            <title>Primary Cohort: RSVpreF 120 mcg + CpG/Al(OH)3 + SIIV</title>
            <description>Participants were administered an intramuscular dose of RSVpreF 120 mcg with CpG/Al(OH)3 as 0.5-mL injection along with single 0.5 mL intramuscular dose of SIIV on Day 1. Participants were followed-up through Month 12.</description>
          </group>
          <group group_id="O5">
            <title>Primary Cohort: RSVpreF 240 mcg + Al(OH)3 + SIIV</title>
            <description>Participants were administered an intramuscular dose of RSVpreF 240 mcg with Al(OH)3 as 0.5-mL injection along with single 0.5 mL intramuscular dose of SIIV on Day 1. Participants were followed-up through Month 12.</description>
          </group>
          <group group_id="O6">
            <title>Primary Cohort: RSVpreF 240 mcg + CpG/Al(OH)3 + SIIV</title>
            <description>Participants were administered an intramuscular dose of RSVpreF 240 mcg with CpG/Al(OH)3 as 0.5-mL injection along with single 0.5 mL intramuscular dose of SIIV on Day 1. Participants were followed-up through Month 12.</description>
          </group>
          <group group_id="O7">
            <title>Primary Cohort: RSVpreF 240 mcg + SIIV</title>
            <description>Participants were administered an intramuscular dose of RSVpreF 240 mcg as 0.5-mL injection along with single 0.5 mL intramuscular dose of SIIV on Day 1. Participants were followed-up through Month 12.</description>
          </group>
          <group group_id="O8">
            <title>Primary Cohort: Placebo + SIIV</title>
            <description>Participants were administered an intramuscular dose of placebo intramuscularly as 0.5-mL injection along with single 0.5 mL intramuscular dose of SIIV on Day 1. Participants were followed-up through Month 12.</description>
          </group>
        </group_list>
        <measure>
          <title>Primary Cohort: Hemagglutination Inhibition Assay (HAI) and Neutralizing Antibody Geometric Mean Titers for All Strains Following the Seasonal Inactivated Influenza Vaccine (SIIV) Before and 1 Month After Vaccination 1</title>
          <description>The HAI and neutralizing titer LLOQ value for each strain was 1:10. Assay results below the LLOQ were set to 0.5 × LLOQ. The analysis was performed on following strains: H1N1 A/Michigan, H3N2 A/Brisbane, B/Phuket for HAI and H3N2/Brisbane for neutralizing assay.</description>
          <population>Evaluable immunogenicity population: participants who received both SIIV and RSV vaccinations or SIIV and placebo as randomized, had blood drawn within 27-42 days after Visit 1 pre-specified time frames at 1-month post-vaccination follow-up visit, had at least 1 valid, determinate assay result for analysis, had no major protocol violations. Number Analyzed = participants evaluable for each specified row. Data for this outcome was planned to be collected for Primary cohort only.</population>
          <units>titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="32"/>
                <count group_id="O3" value="32"/>
                <count group_id="O4" value="31"/>
                <count group_id="O5" value="31"/>
                <count group_id="O6" value="29"/>
                <count group_id="O7" value="31"/>
                <count group_id="O8" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HAI: H1N1 A/Michigan: Before Vaccination 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="29"/>
                    <count group_id="O2" value="31"/>
                    <count group_id="O3" value="32"/>
                    <count group_id="O4" value="31"/>
                    <count group_id="O5" value="31"/>
                    <count group_id="O6" value="29"/>
                    <count group_id="O7" value="31"/>
                    <count group_id="O8" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.9" lower_limit="31.69" upper_limit="72.26"/>
                    <measurement group_id="O2" value="42.8" lower_limit="27.81" upper_limit="65.78"/>
                    <measurement group_id="O3" value="29.5" lower_limit="19.03" upper_limit="45.84"/>
                    <measurement group_id="O4" value="35.8" lower_limit="22.14" upper_limit="57.77"/>
                    <measurement group_id="O5" value="37.2" lower_limit="22.99" upper_limit="60.19"/>
                    <measurement group_id="O6" value="31.9" lower_limit="18.31" upper_limit="55.48"/>
                    <measurement group_id="O7" value="38.3" lower_limit="27.20" upper_limit="53.80"/>
                    <measurement group_id="O8" value="35.4" lower_limit="20.37" upper_limit="61.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HAI: H1N1 A/Michigan: 1 Month After Vaccination 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="29"/>
                    <count group_id="O2" value="32"/>
                    <count group_id="O3" value="32"/>
                    <count group_id="O4" value="31"/>
                    <count group_id="O5" value="31"/>
                    <count group_id="O6" value="29"/>
                    <count group_id="O7" value="31"/>
                    <count group_id="O8" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="121.5" lower_limit="84.37" upper_limit="175.11"/>
                    <measurement group_id="O2" value="114.4" lower_limit="79.95" upper_limit="163.60"/>
                    <measurement group_id="O3" value="102.1" lower_limit="69.15" upper_limit="150.65"/>
                    <measurement group_id="O4" value="141.5" lower_limit="90.54" upper_limit="221.13"/>
                    <measurement group_id="O5" value="143.9" lower_limit="91.81" upper_limit="225.51"/>
                    <measurement group_id="O6" value="100.4" lower_limit="74.68" upper_limit="134.96"/>
                    <measurement group_id="O7" value="118.3" lower_limit="84.12" upper_limit="166.40"/>
                    <measurement group_id="O8" value="149.3" lower_limit="104.93" upper_limit="212.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HAI: H3N2 A/Brisbane: Before Vaccination 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="29"/>
                    <count group_id="O2" value="31"/>
                    <count group_id="O3" value="32"/>
                    <count group_id="O4" value="31"/>
                    <count group_id="O5" value="31"/>
                    <count group_id="O6" value="29"/>
                    <count group_id="O7" value="31"/>
                    <count group_id="O8" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="121.6" lower_limit="67.92" upper_limit="217.54"/>
                    <measurement group_id="O2" value="143.9" lower_limit="90.99" upper_limit="227.52"/>
                    <measurement group_id="O3" value="57.8" lower_limit="35.11" upper_limit="95.19"/>
                    <measurement group_id="O4" value="80.9" lower_limit="53.49" upper_limit="122.38"/>
                    <measurement group_id="O5" value="102.3" lower_limit="61.32" upper_limit="170.69"/>
                    <measurement group_id="O6" value="90.7" lower_limit="53.21" upper_limit="154.57"/>
                    <measurement group_id="O7" value="121.7" lower_limit="87.32" upper_limit="169.55"/>
                    <measurement group_id="O8" value="76.8" lower_limit="45.79" upper_limit="128.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HAI: H3N2 A/Brisbane: 1 Month After Vaccination 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="29"/>
                    <count group_id="O2" value="32"/>
                    <count group_id="O3" value="32"/>
                    <count group_id="O4" value="31"/>
                    <count group_id="O5" value="31"/>
                    <count group_id="O6" value="29"/>
                    <count group_id="O7" value="31"/>
                    <count group_id="O8" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="297.9" lower_limit="197.30" upper_limit="449.64"/>
                    <measurement group_id="O2" value="372.4" lower_limit="221.98" upper_limit="624.70"/>
                    <measurement group_id="O3" value="238.9" lower_limit="167.42" upper_limit="340.78"/>
                    <measurement group_id="O4" value="251.6" lower_limit="163.84" upper_limit="386.49"/>
                    <measurement group_id="O5" value="327.2" lower_limit="208.41" upper_limit="513.80"/>
                    <measurement group_id="O6" value="258.1" lower_limit="174.20" upper_limit="382.29"/>
                    <measurement group_id="O7" value="286.2" lower_limit="201.75" upper_limit="405.87"/>
                    <measurement group_id="O8" value="321.8" lower_limit="221.41" upper_limit="467.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HAI: B/Phuket: Before Vaccination 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="29"/>
                    <count group_id="O2" value="31"/>
                    <count group_id="O3" value="32"/>
                    <count group_id="O4" value="31"/>
                    <count group_id="O5" value="31"/>
                    <count group_id="O6" value="29"/>
                    <count group_id="O7" value="31"/>
                    <count group_id="O8" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.7" lower_limit="6.37" upper_limit="11.78"/>
                    <measurement group_id="O2" value="8.4" lower_limit="6.68" upper_limit="10.59"/>
                    <measurement group_id="O3" value="6.6" lower_limit="5.61" upper_limit="7.82"/>
                    <measurement group_id="O4" value="7.9" lower_limit="6.31" upper_limit="9.79"/>
                    <measurement group_id="O5" value="8.6" lower_limit="6.57" upper_limit="11.25"/>
                    <measurement group_id="O6" value="7.3" lower_limit="5.55" upper_limit="9.69"/>
                    <measurement group_id="O7" value="9.1" lower_limit="6.82" upper_limit="12.11"/>
                    <measurement group_id="O8" value="7.5" lower_limit="5.74" upper_limit="9.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HAI: B/Phuket: 1 Month After Vaccination 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="29"/>
                    <count group_id="O2" value="32"/>
                    <count group_id="O3" value="32"/>
                    <count group_id="O4" value="31"/>
                    <count group_id="O5" value="31"/>
                    <count group_id="O6" value="29"/>
                    <count group_id="O7" value="31"/>
                    <count group_id="O8" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.3" lower_limit="8.99" upper_limit="16.90"/>
                    <measurement group_id="O2" value="11.2" lower_limit="8.41" upper_limit="14.92"/>
                    <measurement group_id="O3" value="10.2" lower_limit="8.03" upper_limit="13.00"/>
                    <measurement group_id="O4" value="12.2" lower_limit="8.62" upper_limit="17.15"/>
                    <measurement group_id="O5" value="14.4" lower_limit="10.31" upper_limit="20.05"/>
                    <measurement group_id="O6" value="14.7" lower_limit="10.21" upper_limit="21.30"/>
                    <measurement group_id="O7" value="15.5" lower_limit="10.86" upper_limit="22.02"/>
                    <measurement group_id="O8" value="15.2" lower_limit="10.25" upper_limit="22.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neutralizing assay: H3N2/Brisbane: Before Vaccination 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="29"/>
                    <count group_id="O2" value="31"/>
                    <count group_id="O3" value="32"/>
                    <count group_id="O4" value="31"/>
                    <count group_id="O5" value="31"/>
                    <count group_id="O6" value="29"/>
                    <count group_id="O7" value="31"/>
                    <count group_id="O8" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.4" lower_limit="9.06" upper_limit="16.97"/>
                    <measurement group_id="O2" value="15.5" lower_limit="11.94" upper_limit="20.02"/>
                    <measurement group_id="O3" value="10.2" lower_limit="8.09" upper_limit="12.90"/>
                    <measurement group_id="O4" value="9.3" lower_limit="7.76" upper_limit="11.27"/>
                    <measurement group_id="O5" value="12.4" lower_limit="9.03" upper_limit="16.93"/>
                    <measurement group_id="O6" value="10.1" lower_limit="7.84" upper_limit="13.06"/>
                    <measurement group_id="O7" value="12.2" lower_limit="10.16" upper_limit="14.71"/>
                    <measurement group_id="O8" value="8.7" lower_limit="6.92" upper_limit="10.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neutralizing assay: H3N2/Brisbane: 1 Month After Vaccination 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="29"/>
                    <count group_id="O2" value="32"/>
                    <count group_id="O3" value="32"/>
                    <count group_id="O4" value="31"/>
                    <count group_id="O5" value="31"/>
                    <count group_id="O6" value="29"/>
                    <count group_id="O7" value="31"/>
                    <count group_id="O8" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.3" lower_limit="19.24" upper_limit="38.70"/>
                    <measurement group_id="O2" value="27.4" lower_limit="18.43" upper_limit="40.66"/>
                    <measurement group_id="O3" value="19.1" lower_limit="14.63" upper_limit="25.06"/>
                    <measurement group_id="O4" value="21.4" lower_limit="16.08" upper_limit="28.44"/>
                    <measurement group_id="O5" value="22.1" lower_limit="16.11" upper_limit="30.36"/>
                    <measurement group_id="O6" value="21.2" lower_limit="16.15" upper_limit="27.90"/>
                    <measurement group_id="O7" value="21.9" lower_limit="16.82" upper_limit="28.44"/>
                    <measurement group_id="O8" value="26.7" lower_limit="18.74" upper_limit="38.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Local reactions and systemic events: within 14 days after vaccination Other AEs: within one month after vaccination; SAEs: Day 1 up to 12 Months for Primary Cohort; Day 1 up to 6 Months for Month-0, Month-2 Cohort</time_frame>
      <desc>Same event may appear as both an AE and SAE. However, what is presented are distinct events. An event may be categorized as serious in 1 participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event. Safety population included all participants who received at least 1 dose of the investigational products (RSVpreF or placebo) at Visit 1.</desc>
      <group_list>
        <group group_id="E1">
          <title>Primary Cohort: RSVpreF 60 mcg + Al(OH)3 + SIIV</title>
          <description>Participants were administered an intramuscular dose of respiratory syncytial virus stabilized prefusion F subunit (RSVpreF) 60 microgram (mcg) with aluminum hydroxide (Al[OH]3) by injecting 0.5 milliliter (mL) dose along with single 0.5mL intramuscular dose of SIIV on Day 1. Participants were followed-up through Month 12.</description>
        </group>
        <group group_id="E2">
          <title>Primary Cohort: RSVpreF 60 mcg + CpG/Al(OH)3 + SIIV</title>
          <description>Participants were administered an intramuscular dose of RSVpreF 60 mcg with CpG/Al(OH)3 as 0.5-mL injection along with single 0.5 mL intramuscular dose of SIIV on Day 1. Participants were followed-up through Month 12.</description>
        </group>
        <group group_id="E3">
          <title>Primary Cohort: RSVpreF 120 mcg + Al(OH)3 + SIIV</title>
          <description>Participants were administered an intramuscular dose of RSVpreF 120 mcg with Al(OH)3 as 0.5-mL injection along with single 0.5 mL intramuscular dose of SIIV on Day 1. Participants were followed-up through Month 12.</description>
        </group>
        <group group_id="E4">
          <title>Primary Cohort: RSVpreF 120 mcg + CpG/Al(OH)3 + SIIV</title>
          <description>Participants were administered an intramuscular dose of RSVpreF 120 mcg with CpG/Al(OH)3 as 0.5-mL injection along with single 0.5 mL intramuscular dose of SIIV on Day 1. Participants were followed-up through Month 12.</description>
        </group>
        <group group_id="E5">
          <title>Primary Cohort: RSVpreF 240 mcg + Al(OH)3 + SIIV</title>
          <description>Participants were administered an intramuscular dose of RSVpreF 240 mcg with Al(OH)3 as 0.5-mL injection along with single 0.5 mL intramuscular dose of SIIV on Day 1. Participants were followed-up through Month 12.</description>
        </group>
        <group group_id="E6">
          <title>Primary Cohort: RSVpreF 240 mcg + CpG/Al(OH)3 + SIIV</title>
          <description>Participants were administered an intramuscular dose of RSVpreF 240 mcg with CpG/Al(OH)3 as 0.5-mL injection along with single 0.5 mL intramuscular dose of SIIV on Day 1. Participants were followed-up through Month 12.</description>
        </group>
        <group group_id="E7">
          <title>Primary Cohort: RSVpreF 240 mcg + SIIV</title>
          <description>Participants were administered an intramuscular dose of RSVpreF 240 mcg as 0.5-mL injection along with single 0.5 mL intramuscular dose of SIIV on Day 1. Participants were followed-up through Month 12.</description>
        </group>
        <group group_id="E8">
          <title>Primary Cohort: Placebo + SIIV</title>
          <description>Participants were administered an intramuscular dose of placebo intramuscularly as 0.5-mL injection along with single 0.5 mL intramuscular dose of SIIV on Day 1. Participants were followed-up through Month 12.</description>
        </group>
        <group group_id="E9">
          <title>Month-0, Month-2 Cohort: RSVpreF 240 mcg + CpG/Al(OH)3</title>
          <description>Participants were administered an intramuscular dose of RSVpreF 240 mcg with CpG/Al(OH)3 as 0.5-mL injection on Day 1 Month 0 (Vaccination 1) and Month 2 (Vaccination 2: 54 to 66 Days after Vaccination 1). Participants were followed up through 6 months after Vaccination 2.</description>
        </group>
        <group group_id="E10">
          <title>Month-0, Month-2 Cohort: Placebo</title>
          <description>Participants were administered an intramuscular dose of placebo as 0.5-mL injection on Day 1 Month 0 (Vaccination 1) and Month 2 (Vaccination 2: 54 to 66 Days after Vaccination 1). Participants were followed up through 6 months after Vaccination 2.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA v23.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="32"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="31"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="30"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="30"/>
                <counts group_id="E9" subjects_affected="6" subjects_at_risk="32"/>
                <counts group_id="E10" subjects_affected="5" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Coronary artery occlusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Colitis ischaemic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Femoral hernia incarcerated</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Large intestine polyp</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaphylactic reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Escherichia sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Medical device site joint infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Facial bones fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Limb injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Post procedural haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Skin laceration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetic ketoacidosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Cervical spinal stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Clear cell renal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Endometrial cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Oesophageal squamous cell carcinoma metastatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Triple negative breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Morton's neuralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Product Issues</title>
            <event_list>
              <event>
                <sub_title>Device breakage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Bladder disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Ureterolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Atelectasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA v23.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="21" subjects_at_risk="32"/>
                <counts group_id="E4" subjects_affected="21" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="17" subjects_at_risk="31"/>
                <counts group_id="E6" subjects_affected="12" subjects_at_risk="30"/>
                <counts group_id="E7" subjects_affected="25" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="14" subjects_at_risk="30"/>
                <counts group_id="E9" subjects_affected="28" subjects_at_risk="32"/>
                <counts group_id="E10" subjects_affected="23" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Diarrhoea (DIARRHEA)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="32"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="30"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="30"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E10" subjects_affected="4" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Diverticulum</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Nausea (NAUSEA)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="31"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="30"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E10" subjects_affected="4" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Rectal polyp</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Fatigue (FATIGUE)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="32"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="31"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="30"/>
                <counts group_id="E7" subjects_affected="14" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="6" subjects_at_risk="30"/>
                <counts group_id="E9" subjects_affected="12" subjects_at_risk="32"/>
                <counts group_id="E10" subjects_affected="13" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Injection site erythema (REDNESS)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="31"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E9" subjects_affected="5" subjects_at_risk="32"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Injection site pain (PAIN AT INJECTION SITE)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="31"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="30"/>
                <counts group_id="E7" subjects_affected="6" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="30"/>
                <counts group_id="E9" subjects_affected="12" subjects_at_risk="32"/>
                <counts group_id="E10" subjects_affected="4" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Injection site reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Injection site swelling (SWELLING)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E9" subjects_affected="4" subjects_at_risk="32"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Peripheral swelling</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Pyrexia (FEVER)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="32"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E10" subjects_affected="3" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Vaccination site pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Bile duct stone</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Giardiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Parainfluenzae virus infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E10" subjects_affected="4" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Viral diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Arthropod sting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Ligament sprain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Limb injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Meniscus injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Muscle injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Tendon rupture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Gout</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Iron deficiency</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia (JOINT PAIN)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="32"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="30"/>
                <counts group_id="E9" subjects_affected="4" subjects_at_risk="32"/>
                <counts group_id="E10" subjects_affected="7" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Degenerative bone disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Joint swelling</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Myalgia (MUSCLE PAIN)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="32"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="31"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="30"/>
                <counts group_id="E7" subjects_affected="6" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="6" subjects_at_risk="30"/>
                <counts group_id="E9" subjects_affected="6" subjects_at_risk="32"/>
                <counts group_id="E10" subjects_affected="6" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Osteopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Temporomandibular joint syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Tendon disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Tendonitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Malignant melanoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Malignant melanoma in situ</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Melanocytic naevus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Seborrhoeic keratosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Headache (HEADACHE)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="30"/>
                <counts group_id="E7" subjects_affected="12" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E9" subjects_affected="5" subjects_at_risk="32"/>
                <counts group_id="E10" subjects_affected="9" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Nasal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Productive cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Sinus congestion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Actinic keratosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Dermatitis contact</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Drug eruption</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Cataract operation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Skin neoplasm excision</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Tooth extraction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Orthostatic hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Study follow up of the Month-0, Month-2 cohort was terminated early due to sponsor decision, with all participants followed up through 6 months after Vaccination 2.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Pfizer ClinicalTrials.gov Call Center</name_or_title>
      <organization>Pfizer Inc.</organization>
      <phone>1-800-718-1021</phone>
      <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

